1. Introduction {#sec1-ijms-21-03580}
===============

The purpose of this review is to summarize the current knowledge in the field of long non-coding RNAs (lncRNAs) and exosomal-lncRNAs involved in lung diseases such as Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD), asthma, and lung cancer. To this aim, we collected information from RNAseq and microarray data when available. Furthermore, we standardized each gene and microRNA (miRNA) name to the official gene symbols and miRNA nomenclatures.

The following three significant steps describe the overall methodology used to process the literature. First, using the PubMed database, we seek for publications related to lncRNAs in each disease. Secondly, we standardized the gene names using the official gene symbols and the Ensembl identifier. Finally, we overlapped the standardized gene lists from each disease and identified ten lncRNAs associated with at least two of the diseases mentioned above. These ten lncRNAs are H19, MALAT1, MEG3, FENDRR, CDKN2B-AS1, TUG1, HOTAIR, GAS5, LINC00861, and CCDC18-AS1.

After a brief introduction to the diseases mentioned above, we will cover the selected lncRNAs one by one. We will describe their known mechanisms of action, their potential as biomarkers, as well as their involvement in treatment resistances. We will then compile the three steps into interaction networks and tables. Finally, we will report the current knowledge about exosomal lncRNAs in lung cancers. Additionally, we listed all the abbreviations and gene definitions in the abbreviation section with hyperlinks redirecting to [Ensembl](http://www.ensembl.org/), [NONCODE](http://www.noncode.org/), or [HUGO](https://www.genenames.org/) nomenclature databases for the lncRNAs, the [miRBase](http://www.mirbase.org/) database for the miRNAs, and the [KEGG](https://www.genome.jp/kegg/) database for the pathways.

1.1. Overview of Lung Diseases Covered in the Current Review {#sec1dot1-ijms-21-03580}
------------------------------------------------------------

### 1.1.1. Idiopathic Pulmonary Fibrosis (IPF) {#sec1dot1dot1-ijms-21-03580}

Idiopathic pulmonary fibrosis is a progressive fibrosing lung disease of unknown aetiology. It is associated with a high morbidity/mortality rate of 3--5 years without specific anti-fibrotic therapy \[[@B1-ijms-21-03580],[@B2-ijms-21-03580],[@B3-ijms-21-03580],[@B4-ijms-21-03580]\]. The prevalence of IPF in Europe ranged from 1.25 to 23.4 cases per 100,000 while being between 14 and 27.9 cases per 100,000 in the USA. The prevalence appears to increase along with age and to be higher among males than females \[[@B5-ijms-21-03580]\].

Despite new anti-fibrotic therapies reducing its evolution, IPF is still challenging to manage. The main particularity of IPF is its sole lung involvement with typical fibroblastic activation. Nevertheless, the physiopathology is still not well known and needs further translational studies. Additionally, the diagnostic approach remains challenging and requires a multidisciplinary approach, including respiratory specialists, radiologists, pathologists, and thoracic surgeons. Besides, the radiological images can be nonspecific, which often requires a lung biopsy to produce an accurate diagnosis. Subsequently, clinicians are urging for specific biomarkers to diagnose the IPF at an early stage to identify patients with a high risk of a rapid flare-up \[[@B6-ijms-21-03580],[@B7-ijms-21-03580]\].

### 1.1.2. Chronic Obstructive Pulmonary Disease (COPD) {#sec1dot1dot2-ijms-21-03580}

COPD is a chronic inflammatory obstructive lung disease, which will probably become the third leading cause of death in 2030, according to the World Health Organization (WHO). It is linked to smoking habits and is characterized by an airflow limitation, which interferes with normal breathing and reduces the potential of physical activity. In 2010, the scientific community estimated the prevalence of COPD at 384 million cases, with a global incidence of 11.7% at a 95% confidence interval (CI) 8.4--15.0% \[[@B8-ijms-21-03580]\].

The clinicians establish the diagnosis of COPD with the spirometry. This simple test measures how deeply a person can breathe and how fast air can move into and out of the lungs. COPD symptoms associate chronic cough, sputum production, dyspnea, and a history of exposure to risk factors for the disease. The current treatment strategy uses bronchodilators and inhaled corticosteroids in case of a frequent exacerbation. However, for the most severe cases, it remains challenging to reduce the acute exacerbations and airflow limitation, leading to a significant decrease in the patient's quality of life. New biomarkers are, therefore, required to detect patients with a high risk of frequent exacerbations, develop specific targeted therapies ([GOLD guidelines](https://goldcopd.org/)), and improve the global outcome of COPD patients \[[@B9-ijms-21-03580]\].

### 1.1.3. Asthma {#sec1dot1dot3-ijms-21-03580}

Asthma is not a single disease, but a complex chronic inflammatory disease of the airways. Indeed, several subtypes of bronchial asthma, also called phenotypes, have different therapeutic and prognostic implications. According to the Global Initiative for Asthma ([GINA](https://ginasthma.org/)), it affects all age groups of about 5% to 10% of the world population. Asthma is specifically characterized by a transient obstruction of the respiratory tract, secondary to bronchoconstriction, or bronchial inflammation. Inflammatory phenotypes can now classify asthmatic patients and allow personalized therapies, thus urging for the identification of biomarkers linked to the widely prevalent disease \[[@B10-ijms-21-03580]\].

### 1.1.4. Lung Cancer {#sec1dot1dot4-ijms-21-03580}

Lung cancer is still the leading cause of cancer-related death in the world despite new therapeutic progress like checkpoint inhibitors. Its prevalence varies worldwide due to tobacco habits, air quality, race/ethnicity, gender, age, and education/income \[[@B11-ijms-21-03580]\]. In 2018, the WHO reported 2.09 million cases of lung cancers around the world. The two main categories of lung cancer are small-cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). According to [cancer.org](https://www.cancer.org), about 13% of all lung cancers are SCLC, and 84% are NSCLC. The overall survival rate at five years is still \<20% despite new specific anti-tumoral therapies as checkpoint inhibitors. Precisely, the survival rate for the extensive stage of SCLC reaches seven months, whereas it is up to 11 months for the widespread disease of NSCLC. These poor survival rates are mainly due to late-stage diagnosis \[[@B12-ijms-21-03580]\].

Subsequently, a new comprehensive approach of the molecular mechanisms is crucial to identify new therapeutic targets for the patients. Finding new biomarkers is, therefore, one of the primary objectives to detect lung cancer at the earliest stages. Lung cancer-derived exosomes are known to represent the cell of origin in many aspects. They need to be intensively studied to better understand cell-cell communication and cancer proliferation.

1.2. Exosomes {#sec1dot2-ijms-21-03580}
-------------

Exosomes are nanovesicles of about 30--150 nm, which are generated within late endosomes/multivesicular bodies (MVBs). They are released to the extracellular microenvironment through MVB fusion to the plasma membrane and exocytosis \[[@B13-ijms-21-03580],[@B14-ijms-21-03580]\]. These vesicles contain many components of the parental cell, including cell-surface proteins, lipids, metabolites, and genetic material (DNA, mRNA, non-coding RNAs including miRNAs and lncRNA) \[[@B15-ijms-21-03580],[@B16-ijms-21-03580]\]. The secretion of exosomes into biological fluids (e.g., bronchoalveolar lavage fluid, saliva, sputum, plasma) confer them promising diagnostic/prognostic value. In a recent study, the characterization of miRNAs content of exosomes from the sputum of patients with IPF enabled to identify a unique signature of 3 altered miRNAs [hsa-miR-142-3p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000434), [hsa-miR-33a-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000091), and [hsa-let-7d-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000065) \[[@B17-ijms-21-03580]\]. Furthermore, the study of the functional properties of exosomes in the context of lung diseases could open new avenues of therapeutic approaches \[[@B18-ijms-21-03580],[@B19-ijms-21-03580]\]. Depending on their composition, exosomes can maintain cellular homeostasis \[[@B20-ijms-21-03580]\], or alter the functional properties of the recipient cell and impact the progression of the disease \[[@B21-ijms-21-03580],[@B22-ijms-21-03580],[@B23-ijms-21-03580],[@B24-ijms-21-03580]\]. Microenvironment plays an important role in the composition of exosomes. For example, the exposure of lung microenvironment to noxious stimuli (e.g., cigarette smoke (CS), allergens, infections, air pollutants) induces the release of airway exosomes enriched with pro-inflammatory/pro-fibrotic components which participate in the progression of lung diseases \[[@B21-ijms-21-03580],[@B22-ijms-21-03580],[@B23-ijms-21-03580],[@B24-ijms-21-03580]\]. Importantly, with the new RNA technologies combined with the recent efforts to define stable reference genes, we are now able to identify better the differentially expressed exosomal-lncRNAs that are involved in lung diseases \[[@B25-ijms-21-03580],[@B26-ijms-21-03580],[@B27-ijms-21-03580]\].

### 1.2.1. Exosomes Are Essential Actors of Intercellular Communication {#sec1dot2dot1-ijms-21-03580}

By the presence of specific surface components as well as the packaging of proteins, lipids, and genetic material, exosomes are bio-effector units that can regulate the properties of target cells. Distinct mechanisms associated with exosome uptake are involved in intercellular communication \[[@B28-ijms-21-03580],[@B29-ijms-21-03580],[@B30-ijms-21-03580]\]. As described in [Figure 1](#ijms-21-03580-f001){ref-type="fig"}, exosomes can transfer the information to target cells via a receptor-mediated mechanism without the delivery of their content. For instance, the high level of Intercellular Adhesion Molecule 1 on exosomes, from mature dendritic cells (DCs), is critical for efficient naive T-cell priming \[[@B31-ijms-21-03580]\]. Furthermore, DC-derived exosomes can carry functional major histocompatibility complex class I and class II molecules that can be loaded with specific peptides to activate viral-specific peripheral CD8+ T cells \[[@B31-ijms-21-03580],[@B32-ijms-21-03580]\]. The other mechanisms involved in intercellular communication are the delivery of exosomal cargo to target cells through macropinocytosis \[[@B33-ijms-21-03580],[@B34-ijms-21-03580],[@B35-ijms-21-03580]\], clathrin-dependent endocytosis \[[@B33-ijms-21-03580]\], or membrane fusion \[[@B36-ijms-21-03580]\].

### 1.2.2. Exosomes Are Playing an Essential Role in Lung Diseases {#sec1dot2dot2-ijms-21-03580}

In a physiological context, various cell types from the lung microenvironment participate in the regulation of lung homeostasis via the secretion of exosomes presenting anti-inflammatory/anti-fibrotic properties \[[@B20-ijms-21-03580],[@B37-ijms-21-03580],[@B38-ijms-21-03580],[@B39-ijms-21-03580]\]. Noxious stimuli exposure (e.g., CS, allergens, infections, air pollutants) can impact nucleic acid cargo (miRNAs, lncRNAs) of lung-derived exosomes and alter their protective properties. Indeed, CS exposure induces the alteration of the composition of bronchial epithelial-derived exosomes composition, with an upregulation of [hsa-miR-21](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000077) and [hsa-miR-210](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000286) \[[@B22-ijms-21-03580],[@B23-ijms-21-03580]\], which in turn dysregulates several cellular processes associated with the progression of the COPD. In the asthma context, several studies have reported an alteration of inflammatory-related exosomal miRNAs from airway biofluids (BALF, and sputum supernatants) \[[@B21-ijms-21-03580],[@B24-ijms-21-03580]\]. In conclusion, lung exosomes released in the pathological context present an alteration of their composition, which in turn may impact the progression of lung diseases.

1.3. Long Non-Coding Rnas {#sec1dot3-ijms-21-03580}
-------------------------

Thanks to an international effort through the FANTOM ([fantom.gsc.riken.jp](http://fantom.gsc.riken.jp)) and the ENCODE ([encodeproject.org](https:/www.encodeproject.org)) projects, we know that the non-coding sequences cover 98% of the human genome and that the transcribed part alone covers 90%. Within these RNA sequences that lack protein-coding capacities, lncRNAs are any expressed RNAs of more than 200 nt in length \[[@B40-ijms-21-03580],[@B41-ijms-21-03580]\]. The current classification of lncRNAs gathers five categories, according to their original genomic location in regards to their corresponding protein-coding gene. These five categories are • intergenic, • intronic, • sense, • antisense, and • bidirectional \[[@B42-ijms-21-03580]\]. According to the NONCODE ([noncode.org](http://www.noncode.org)) database file "NONCODEv5_human_hg38_lncRNA.gtf", 172,216 lncRNA transcripts can theoretically be found in humans \[[@B43-ijms-21-03580]\]. From our literature screening in January 2020, we found hundreds of them potentially associated with COPD, asthma, IPF, or lung cancer. This review focuses on the lncRNAs commonly found between these four lung diseases. While we will summarize their mechanisms of action regarding these diseases, additional studies may also help to understand the full picture of lncRNAs \[[@B42-ijms-21-03580],[@B44-ijms-21-03580],[@B45-ijms-21-03580],[@B46-ijms-21-03580],[@B47-ijms-21-03580]\].

### 1.3.1. Transcript-Regulating LncRNAs {#sec1dot3dot1-ijms-21-03580}

Under the mRNA transcript degradation process, mature miRNAs bind to the Argonaute RISC Catalytic Components 1 to 4 ([AGO1-4](https://www.ncbi.nlm.nih.gov/gene/?term=(Human)+AND+(Argonaute+RISC))). This complex will then target an mRNA 3'UTR leading to the degradation of the mRNA. However, transcript-regulating lncRNAs (treg-lncRNAs) can prevent such mRNA degradation. The lncRNA can act as an RNA decoy for a miRNA, leading to a • miRNA sequestration, • miRNA degradation, or a • translational repression of the mRNA \[[@B48-ijms-21-03580]\]. The miRNA sequestration and the miRNA degradation are part of the competing endogenous RNA (ceRNA) network, which aims at circumventing miRNAs from their original targets \[[@B49-ijms-21-03580]\]. The sequestration controls the miRNA abundance in the cell and inhibits its activity \[[@B41-ijms-21-03580]\]. This process also called "miRNA sponge", happens just before a miRNA could regulate its target mRNAs through a physical binding between the lncRNA and the miRNA. More precisely, the miRNA binding site, located in the 3'UTR of the lncRNA, does not allow for the degradation of the lncRNA, as it would occur for protein-coding transcripts. Instead, mismatched nucleotides in the lncRNA binding site lead to sequestration of the miRNA by the lncRNA. Subsequently, a sufficient amount of lncRNAs would act as a "sponge," disabling the mRNA regulation by the sequestrated miRNA \[[@B41-ijms-21-03580]\]. Furthermore, one lncRNA can have multiple miRNA targets, and circular lncRNAs can also regulate the miRNA activity \[[@B47-ijms-21-03580]\]. Interestingly, lncRNAs may be involved in positive feedback loops while targeting miRNAs. For example, a recent study by Qu et al. describes the upregulation of lncRNA [ZEB1-AS1](http://www.ensembl.org/id/ENSG00000237036) observed in NSCLC cells. ZEB1-AS1 can sequester the miRNA [hsa-miR-409-3p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0001639), which leads to an increase in the mRNA and protein levels of [ZEB1](http://www.ensembl.org/id/ENSG00000148516). In return, ZEB1 binds the promoter region of ZEB1-AS1 and activates its expression \[[@B50-ijms-21-03580]\].

*NAT-lncRNAs Specific Regulation:* Few mechanisms may be specific to Natural Antisense transcripts (NATs). NATs are RNA sequences that are complementary to and overlap with either protein-coding or non-coding transcripts \[[@B42-ijms-21-03580],[@B51-ijms-21-03580]\]. Cis-NATs are transcribed from the same genomic locus and have a perfect complementarity with their target mRNA transcript. Trans-NATs are transcribed from a different genomic locus and have an imperfect complementarity with their target mRNA transcript \[[@B42-ijms-21-03580]\]. The NATs may act on the transcription through transcriptional interference, RNA masking, and RNA "A to I" editing \[[@B42-ijms-21-03580]\]. NATs may also regulate the abundance of mRNAs by • suppressing the translation through polysome displacing, • promoting the mRNA decay through 3'UTR binding, or • modulating the mRNA stability and increasing its expression level through the formation of sense or antisense pairs \[[@B44-ijms-21-03580]\]. While the majority of the studies described their actions in cis, no study invalidates a possible operation in trans.

### 1.3.2. Epigenetics-Regulating LncRNAs {#sec1dot3dot2-ijms-21-03580}

Epigenetics-regulating lncRNAs (epi-lncRNAs) are lncRNAs that may guide the polycomb chromatin domains until polynucleosome compaction \[[@B42-ijms-21-03580],[@B52-ijms-21-03580]\]. The Polycomb group of proteins was identified as a transcriptional-repressive complex, named the Polycomb Repressive Complex (PRC). Essential members of the PRC are the PRC1 and PRC2. The PRC1 contains the [CBX7](http://www.ensembl.org/id/ENSG00000100307) protein, and the PRC2 contains the [EZH1](http://www.ensembl.org/id/ENSG00000108799), [EZH2](http://www.ensembl.org/id/ENSG00000106462), [EED](http://www.ensembl.org/id/ENSG00000074266), and the [SUZ12](http://www.ensembl.org/id/ENSG00000178691) subunits. Importantly, the PRC2 is highly conserved between plants and animals and can create polycomb chromatin domains with the PRC1 to help polynucleosome compaction \[[@B53-ijms-21-03580]\]. Indeed, PRC1's CBX7 and PRC2's EZH2-SUZ12 can tether epi-lncRNAs, which in return will guide the polycomb chromatin domain through its repressive action. Then, PRC2's EZH2 and EZH1 trimethylates the histone 3 at lysine 27 (H3K27me3), which will become an anchor site for the PRC1. Once the PRC1 is attached, it mono-ubiquitinates the H2A on K119 (H2AK119Ub), eventually leading to the repression of the targeted gene \[[@B42-ijms-21-03580],[@B53-ijms-21-03580]\]. However, the PRC2 may tether many types of RNA without a precise binding site. In consequence, assigning only the lncRNAs to the recruitment of the PRC2 may be premature \[[@B54-ijms-21-03580]\]. Moreover, epi-lncRNAs may regulate gene expressions independently \[[@B47-ijms-21-03580]\]. For example, HOTAIR can repress a limited number of genes through H3K27me3 without the involvement of the PRC2 complex \[[@B55-ijms-21-03580]\]. Hence, these recent observations point up the need for a better understanding of the epigenetics modulation triggered by epi-lncRNAs.

Besides, the lncRNAs are generally expressed at low levels when compared to protein-coding genes \[[@B56-ijms-21-03580],[@B57-ijms-21-03580]\]. This low expression underlines a fine regulation of their target mRNA, which could dramatically impact the behavior of the receiving cell during intercellular communication. However, the mechanisms are not clear enough to understand how an epi-lncRNAs, which acts in the nucleus, can reach its targets in another cell through vesicle transportation.

2. LncRNAs and Their Exosomes in Lung Diseases {#sec2-ijms-21-03580}
==============================================

From a PubMed screening, done in January 2020, we found associations only between lung cancers and both lncRNAs and exosomes. Therefore, our strategy was first to build a list of the most published lncRNAs found in at least two lung diseases within asthma, COPD, IPF, and lung cancers. Importantly, this information comes from either the main text, the figures, or the gene expression datasets that were available. After overlapping the official gene symbols, we found the ten following lncRNAs in at least two diseases: H19, MALAT1, MEG3, FENDRR, CDKN2B-AS1, TUG1, HOTAIR, GAS5, LINC00861, and CCDC18-AS1. Interestingly, we did not find publications reporting LINC00861 and CCDC18-AS1 in lung cancers.

Hereafter we will describe the ten lncRNAs in their associated disease. We will then summarize the eight lncRNAs found in lung cancers into interaction networks and tables listing their promising clinical interests. [Figure 2](#ijms-21-03580-f002){ref-type="fig"}, [Figure 3](#ijms-21-03580-f003){ref-type="fig"} and [Figure 4](#ijms-21-03580-f004){ref-type="fig"} summarize these lncRNAs and their known actions in the COPD, IPF, and asthma, respectively. Dedicated networks will then cover each of these lncRNAs in lung cancers. [Table 1](#ijms-21-03580-t001){ref-type="table"} and [Table 2](#ijms-21-03580-t002){ref-type="table"} respectively provide the downstream targets of the eight lncRNAs and their possible use as biomarkers in the lung diseases mentioned above. [Table 3](#ijms-21-03580-t003){ref-type="table"} provides lung cancer treatment resistances associated with the eight lncRNAs. Moreover, from this list, only H19, MALAT1, HOTAIR, and GAS5 were associated with exosomes and lung cancers in our PubMed search. Therefore, we will also shortly describe results on exosomes for six additional lncRNAs that were related to only lung cancers. These lncRNAs are UCA1, lnc-MMP2-2, GAPLINC, TBILA, AGAP2-AS1, and SOX2-OT.

2.1. H19 {#sec2dot1-ijms-21-03580}
--------

H19 Imprinted Maternally Expressed Transcript ([H19](http://www.ensembl.org/id/ENSG00000130600)) is an RNA gene localized on the cytogenetic band 11p15.5, in an imprinted region and is close to the [IGF2](http://www.ensembl.org/id/ENSG00000167244) gene. H19 is maternally-imprinted, whereas IGF2 is paternally-imprinted. H19 gene has 12 transcripts, 3 retained introns, and 9 lncRNAs \[[@B122-ijms-21-03580],[@B123-ijms-21-03580],[@B124-ijms-21-03580]\]. Interestingly, in human adrenocortical carcinoma cell lines (NCI-H295R), the induction of H19 gene expression comes along with a decrease of IGF2 expression, suggesting a direct mRNA expression regulation \[[@B125-ijms-21-03580]\].

### 2.1.1. H19 and IPF {#sec2dot1dot1-ijms-21-03580}

In human pulmonary fibrotic tissues from IPF patients, H19 is upregulated and induces fibrosis using the [TGFB/SMAD3 signaling pathway](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04350), through [hsa-miR-140](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000456) sequestration. Indeed, the hsa-miR-140 can repress the mRNA and protein expressions of [TGFB1](http://www.ensembl.org/id/ENSG00000105329) and phospho-[SMAD3](http://www.ensembl.org/id/ENSG00000166949) \[[@B65-ijms-21-03580]\]. Moreover, in TGFB1 induced fibroblasts, H19 upregulation releases [COL1A1](http://www.ensembl.org/id/ENSG00000108821) expression through hsa-miR-196a ([hsa-miR-196a-1](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000238) or [hsa-miR-196a-2](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000279)) sequestration, thus leading to increase cell proliferation and migration \[[@B126-ijms-21-03580]\].

### 2.1.2. H19 and Asthma {#sec2dot1dot2-ijms-21-03580}

Austin et al. found H19 downregulated in airway smooth muscle (ASM) cells from non-severe asthma when compared to healthy patients. Please refer to their microarray experiment in supplemental Table 10 \[[@B127-ijms-21-03580]\]. However, the authors did not focus on H19 in their study, which requires further efforts to assess its clinical impact and mechanism of action.

### 2.1.3. H19 and COPD {#sec2dot1dot3-ijms-21-03580}

H19 is upregulated in the quadriceps of the low fat-free mass index (FFMI) COPD patients when compared to normal FFMI. H19 hosts the [hsa-miR-675](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0005416), a miRNA also upregulated in low FFMI COPD patients. The increase of H19 expression may be the consequence of an altered methylation of its region. Besides, H19 expression is associated with the downregulation of [MYOD1](http://www.ensembl.org/id/ENSG00000129152) and hsa-miR-519a ([hsa-miR-519a-1](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0003178) or [hsa-miR-519a-2](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0003182)) in male patients with severe COPD \[[@B68-ijms-21-03580]\]. Subsequently, we can suspect that H19 sequester hsa-miR-519a following demethylation, thus contributing to increase the susceptibility to a low FFMI for the COPD patients.

### 2.1.4. H19 and Lung Cancer {#sec2dot1dot4-ijms-21-03580}

Several studies described H19 as upregulated in NSCLC cells and tumors tissues. They demonstrated that H19 induces cell proliferation, migration, viability, invasion, and epithelial-mesenchymal transition (EMT) while decreasing apoptosis \[[@B128-ijms-21-03580],[@B129-ijms-21-03580],[@B130-ijms-21-03580],[@B131-ijms-21-03580],[@B132-ijms-21-03580],[@B133-ijms-21-03580],[@B134-ijms-21-03580]\]. H19 uses the following mechanisms, as summarized in [Figure 5](#ijms-21-03580-f005){ref-type="fig"}. ⋄**Regulators of H19:** In NSCLC tumor tissues, [FOXF2](http://www.ensembl.org/id/ENSG00000137273) can bind the promoter of H19 and can increase its expression, causing a PTEN downregulation \[[@B135-ijms-21-03580]\]. Additionally, H19 may be a direct transcriptional target of and is induced by [MYC](http://www.ensembl.org/id/ENSG00000136997) in NSCLC tumor tissues. Indeed, MYC binds to H19 promoter's E-boxes to facilitate histone acetylation and transcriptional initiation. Furthermore, MYC can downregulate the expression of IGF2 independently \[[@B136-ijms-21-03580],[@B137-ijms-21-03580]\]. Besides, Shahdoust et al. found H19 among the seven most differentially expressed lncRNAs in the human airway epithelium of cigarette smokers when compared to non-smokers \[[@B138-ijms-21-03580]\]. Similar results, obtained in cdk-4/hTERT-immortalized human bronchial epithelial cells (HBEC), described the H19 upregulation following prolonged CSC exposure. Interestingly, the same authors also found a general diminution of H4K16ac and H4K20me3 and an overall increase of H3K27me3 levels \[[@B74-ijms-21-03580]\]. Nevertheless, H19 methylation status remains low, as [RIOX2](http://www.ensembl.org/id/ENSG00000170854) can remove methyl groups from H3K9me3 on the H19 promoter, leading to de-repress H19 transcription \[[@B139-ijms-21-03580]\]. Importantly, Liu et al. suggested that H19 demethylation may precede the methylations that silence tumor suppressor genes such as p16-[CDKN2A](http://www.ensembl.org/id/ENSG00000147889), [MGMT](http://www.ensembl.org/id/ENSG00000170430), [DAPK](http://www.ensembl.org/id/ENSG00000196730), E-cadherin ([CDH1](http://www.ensembl.org/id/ENSG00000039068)), and [CDH13](http://www.ensembl.org/id/ENSG00000140945) \[[@B74-ijms-21-03580]\]. Moreover, the histone alterations coincided with a decreased [DNMT1](http://www.ensembl.org/id/ENSG00000130816) and an increased [DNMT3B](http://www.ensembl.org/id/ENSG00000088305) expressions, as well as the activation of the WNT/*β*-catenin signaling pathway during prolonged CSC exposure \[[@B74-ijms-21-03580]\]. Indeed, the authors found that WNT ligands, such as [WNT2](http://www.ensembl.org/id/ENSG00000105989), [WNT5A](http://www.ensembl.org/id/ENSG00000114251), [WNT6](http://www.ensembl.org/id/ENSG00000115596), and [WNT10A](http://www.ensembl.org/id/ENSG00000135925), and the Wnt signaling targets [FOXN1](http://www.ensembl.org/id/ENSG00000109101) and [TCF7](http://www.ensembl.org/id/ENSG00000081059), were up-regulated \[[@B74-ijms-21-03580]\].⋄**H19 regulated genes:** In NSCLC tumor tissues, H19 decreases the expression of CDH1 by inducing its promoter methylation and also increases CDH2 and VIM expressions \[[@B134-ijms-21-03580],[@B140-ijms-21-03580]\]. Moreover, in human NSCLC cell lines (A549), H19 may regulate metastasis through the modulation of cell proliferation and cell adhesion proteins, including [MACC1](http://www.ensembl.org/id/ENSG00000183742), [EGFR](http://www.ensembl.org/id/ENSG00000146648), $\beta$-catenin ([CTNNB1](http://www.ensembl.org/id/ENSG00000168036)), ERK1 ([MAPK3](http://www.ensembl.org/id/ENSG00000102882)) and ERK2 ([MAPK1](http://www.ensembl.org/id/ENSG00000100030)) \[[@B141-ijms-21-03580]\].⋄**H19 recruits the PRC2:** In NSCLC tumor tissues, H19 can recruit EZH2 to repress [PTEN](http://www.ensembl.org/id/ENSG00000171862) expression, thus increasing cell proliferation \[[@B135-ijms-21-03580]\].⋄**H19 as ceRNA:** Among its known functions, H19 was reported as a heavy miRNA regulator. Indeed, H19 can sequester: • [hsa-miR-107](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000114), to release the expression of [NF1](http://www.ensembl.org/id/ENSG00000196712) in NSCLC tumor tissues \[[@B128-ijms-21-03580]\] • [hsa-miR-200a](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000737), to release the expression of [ZEB1](http://www.ensembl.org/id/ENSG00000148516) and [ZEB2](http://www.ensembl.org/id/ENSG00000169554) in NSCLC tumor tissues \[[@B130-ijms-21-03580]\] • [hsa-miR-29b-3p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000100) and [hsa-miR-17](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000071), to release the expression of [STAT3](http://www.ensembl.org/id/ENSG00000168610) in NSCLC tumor tissues \[[@B131-ijms-21-03580],[@B132-ijms-21-03580]\] • [hsa-miR-196b](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0001150) to release the expression of [LIN28B](http://www.ensembl.org/id/ENSG00000187772) and induce cell growth in NSCLC tumor tissues \[[@B142-ijms-21-03580]\] • hsa-miR-138 (MIR138-1, [MI0000476](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000476) or MIR138-2, [MI0000455](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000455)) to release the expression of [PDK1](http://www.ensembl.org/id/ENSG00000152256) in NSCLC tumor tissues \[[@B129-ijms-21-03580]\] • [hsa-miR-484](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0002468) to release the expression of [ROCK2](http://www.ensembl.org/id/ENSG00000134318) and increase the levels of phosphorylated [JUN](http://www.ensembl.org/id/ENSG00000177606) as well as the mesenchymal markers N-cadherin ([CDH2](http://www.ensembl.org/id/ENSG00000170558)), vimentin ([VIM](http://www.ensembl.org/id/ENSG00000026025)), ZEB1 and [SNAI1](http://www.ensembl.org/id/ENSG00000124216) while decreasing the level of the epithelial marker CDH1 in NSCLC tumor tissues and cell lines \[[@B133-ijms-21-03580],[@B134-ijms-21-03580],[@B143-ijms-21-03580]\]. A similar observation can be made with the downregulation of hsa-miRNA-203 ([hsa-miRNA-203a](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000283) or [hsa-miRNA-203b](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0017343)), which was associated with VIM and SNAI1 upregulation and CDH1 downregulation in NSCLC tumor tissues \[[@B143-ijms-21-03580]\].⋄**19 as a miRNA regulator:** In NSCLC tumor tissues, H19 induces [hsa-miR-675-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0004284) expression, which, in turn, increases the expression of [BCL2](http://www.ensembl.org/id/ENSG00000171791) and decreases the expression of [TP53](http://www.ensembl.org/id/ENSG00000141510) as well as [BAX](http://www.ensembl.org/id/ENSG00000087088) \[[@B144-ijms-21-03580],[@B145-ijms-21-03580],[@B146-ijms-21-03580]\]. Xu et al. hypothesized H19 as an epigenetic regulator of [hsa-miR-6515-3p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0025487), which contributes to metastasis \[[@B147-ijms-21-03580]\]. H19 expression was also positively correlated to hsa-miR-21 expression \[[@B97-ijms-21-03580]\].⋄**H19 at the clinical level:** H19 upregulation in NSCLC tumor tissues was associated with advanced tumor--node--metastasis (TNM) stages and negatively correlated with patient Overall Survival (OS) \[[@B96-ijms-21-03580],[@B97-ijms-21-03580]\]. H19 expression was also higher in stage III and IV NSCLC, while hsa-miR-21 expression was higher in stage I and II NSCLC when compared to non-tumor lung tissues \[[@B97-ijms-21-03580]\]. Besides, plasma levels of H19 were significantly increased in NSCLC patients when compared to patients with benign lung disease \[[@B89-ijms-21-03580]\]. Additionally, a nucleotide polymorphism, the H19-rs217727 C\>T, was found significantly associated with an increased risk of lung cancer \[[@B84-ijms-21-03580]\]. Consequently, with further efforts to confirm these results in large independent cohorts, H19 would make a great biomarker to diagnose or to assess a genetic predisposition to lung cancers.⋄**H19 behavior against treatment:** Wang et al. found a negative correlation between the H19 upregulation in NSCLC tumor tissues and the Cisplatin (DDP) response \[[@B96-ijms-21-03580]\].⋄**Exosomal H19:** Tumor-released lncRNA H19 (exo-H19) can promote gefitinib resistance via packaging into exosomes in NSCLCs. While the experiments were on gefitinib-resistant NSCLC cell lines, the authors assessed the expression of H19 in both gefitinib-resistant and parental sensitive cells. H19 expression was increased in gefitinib-resistant NSCLC cells and was described as secreted through the incorporation into exosomes, which was mediated by [HNRNPA2B1](http://www.ensembl.org/id/ENSG00000122566). Moreover, exosome-mediated transfer of H19 conferred gefitinib resistance to the recipient NSCLC cells \[[@B148-ijms-21-03580]\].

2.2. MEG3 {#sec2dot2-ijms-21-03580}
---------

Maternally Expressed 3 ([MEG3](http://www.ensembl.org/id/ENSG00000214548)) is a maternally expressed imprinted RNA gene localized on the cytogenetic band 14q32.2, in the [DLK1](http://www.ensembl.org/id/ENSG00000185559)-[DIO3](http://www.ensembl.org/id/ENSG00000197406) imprinted region. MEG3 gene has 50 transcripts, all identified as lncRNAs. MEG3 is expressed in many tissues under normal conditions and interacts with TP53 \[[@B149-ijms-21-03580]\].

### 2.2.1. MEG3 and IPF {#sec2dot2dot1-ijms-21-03580}

In pulmonary epithelial cells from IPF lung tissue, MEG3 upregulation promotes migration with an upregulation of [TP63](http://www.ensembl.org/id/ENSG00000073282), keratin 14 ([KRT14](http://www.ensembl.org/id/ENSG00000186847)), STAT3, and [YAP1](http://www.ensembl.org/id/ENSG00000137693) as well as a downregulation of [TP73](http://www.ensembl.org/id/ENSG00000078900), [SOX2](http://www.ensembl.org/id/ENSG00000181449), [HES1](http://www.ensembl.org/id/ENSG00000114315), and [HEY1](http://www.ensembl.org/id/ENSG00000164683) \[[@B66-ijms-21-03580]\].

### 2.2.2. MEG3 and Asthma {#sec2dot2dot2-ijms-21-03580}

In CD4${}^{+}$T-cells of asthmatic patients, MEG3 is upregulated when compared to healthy patients. Moreover, it displays pro-inflammatory properties linked to the increase of Th17 associated cytokines [IL17A](http://www.ensembl.org/id/ENSG00000112115) and [IL22](http://www.ensembl.org/id/ENSG00000127318). It acts through hsa-miR-17 sequestration, which in turn releases the expression of ROR$\gamma$t ([RORC](http://www.ensembl.org/id/ENSG00000143365)), leading to an increase of Treg/TH17 \[[@B59-ijms-21-03580]\].

### 2.2.3. MEG3 and COPD {#sec2dot2dot3-ijms-21-03580}

In lung tissues from COPD patients and cigarette smoke extract (CSE)-treated 16HBE cells, MEG3 is upregulated \[[@B70-ijms-21-03580],[@B72-ijms-21-03580]\]. It induces apoptosis and inflammation by releasing inflammatory cytokines IL1$\beta$ ([IL1B](http://www.ensembl.org/id/ENSG00000125538)), [IL6](http://www.ensembl.org/id/ENSG00000136244) and TNF $\alpha$ ([TNF](http://www.ensembl.org/id/ENSG00000232810)) expression through hsa-miR-218 ([hsa-miR-218-1](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000294) or [hsa-miR-218-2](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000295)) sequestration \[[@B70-ijms-21-03580]\].

### 2.2.4. MEG3 and Lung Cancer {#sec2dot2dot4-ijms-21-03580}

Downregulated MEG3 can regulate cell proliferation, EMT, and apoptosis in NSCLC tumor tissues from patients with an advanced pathological stage, as well as in cell lines. Importantly, MEG3 was more downregulated in stages III+IV when compared to stages I+II, and it also increases cell viability and proliferation, while reducing the expression of autophagy \[[@B120-ijms-21-03580]\]. Conversely, MEG3 was significantly less methylated in the tumor of smoker patients with clinical early-stage NSCLC, as compared to non-cancerous tissue. This MEG3 demethylated region (DMR) was associated with a hypermethylated DIO3 and two hypomethylated (DLK1 and [RTL1](http://www.ensembl.org/id/ENSG00000254656)) \[[@B150-ijms-21-03580]\]. Subsequently, the low MEG3 expression observed in NSCLC patients with an advanced pathological stage may be due to a deletion of the MEG3-DMR locus or could be due to the deletion of a transcription factor binding MEG3 promoter \[[@B150-ijms-21-03580],[@B151-ijms-21-03580],[@B152-ijms-21-03580]\]. MEG3 uses the following mechanisms, as summarized in [Figure 6](#ijms-21-03580-f006){ref-type="fig"}. ⋄**Regulators of MEG3:** MEG3 promoter methylation was reported in 96% of NSCLC tumor tissues, which mainly contributes to its downregulation \[[@B153-ijms-21-03580],[@B154-ijms-21-03580]\]. Alternatively, phosphorylated [RB1](http://www.ensembl.org/id/ENSG00000139687) has been described to activate DNMT1, which in turn, will also decrease the methylation of the MEG3 locus \[[@B155-ijms-21-03580]\].⋄**MEG3 regulated genes:** Two studies realized in NSCLC tumor tissues described MEG3 as an activator of TP53 by decreasing the levels of [MDM2](http://www.ensembl.org/id/ENSG00000135679) \[[@B149-ijms-21-03580],[@B153-ijms-21-03580]\]. Additionally, MEG3 can decrease BCL2 expression by promoting BAX, and also decrease [MAP1LC3A](http://www.ensembl.org/id/ENSG00000101460) expression \[[@B156-ijms-21-03580],[@B157-ijms-21-03580]\]. Besides, Su et al. described MEG3 as inversely correlated with [PCNA](http://www.ensembl.org/id/ENSG00000132646) \[[@B153-ijms-21-03580]\].⋄**MEG3 recruits the PRC2:** In NSCLC cell lines, MEG3 contributes to the recruitment of PRC2's EZH2, through a possible interaction with [JARID2](http://www.ensembl.org/id/ENSG00000008083). This PRC2 recruitment will eventually repress the expression of CDH1, ZEB family (ZEB1 and ZEB2), and hsa-miR-200 family ( [MIR200A](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000737), [MIR200B](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000342), and [MIR200C](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000650) ), which will lead to a decreased EMT \[[@B158-ijms-21-03580]\].⋄**MEG3 as ceRNA:** Among its known functions, MEG3 was reported as a heavy miRNA regulator. Indeed, MEG3 can sequester: • [hsa-miR-650](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0003665) to release the expression of [SLC34A2](http://www.ensembl.org/id/ENSG00000157765), in NSCLC cell line (H1299) \[[@B159-ijms-21-03580]\] • [hsa-miR-7-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000252) to release the expression of [BRCA1](http://www.ensembl.org/id/ENSG00000012048), in NSCLC tumor tissues and BEAS-2B, A549, and HCC823 cell lines \[[@B156-ijms-21-03580]\] • [hsa-miR-21-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000076) to release the expression of [SOX7](http://www.ensembl.org/id/ENSG00000012048), in DDP-resistant NSCLC tumor tissues and A549 and H1299 cell lines \[[@B117-ijms-21-03580]\] • [hsa-miR-3163](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0014193) to release the expression of [SKP2](http://www.ensembl.org/id/ENSG00000145604) that will, in turn, promotes the ubiquitination-associated degradation of p27 ([CDKN1B](http://www.ensembl.org/id/ENSG00000111276)), in NSCLC tumor tissues and A549 cell lines \[[@B153-ijms-21-03580]\] • [hsa-miR-205-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000266) to release the expression of [LRP1](http://www.ensembl.org/id/ENSG00000123384). hsa-miR-205-5p may also be involved in the inhibition of TP53, p21 ([CDKN1A](http://www.ensembl.org/id/ENSG00000124762)), and caspase-3 ([CASP3](http://www.ensembl.org/id/ENSG00000164305)) expressions, in NSCLC tumor tissues and MEG3-knockdown NSCLC cell lines \[[@B154-ijms-21-03580],[@B157-ijms-21-03580],[@B160-ijms-21-03580]\]. Moreover, using lncRNA-miRNA-mRNA regulatory network modules, Li et al. showed the following interactions in LUAD tumors from The Cancer Genome Atlas (TCGA). MEG3 and [MIAT](http://www.ensembl.org/id/ENSG00000225783) may interact with hsa-miR-106 ([hsa-miR-106a](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000113) or [hsa-miR-106b](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000734)), which then would regulate the expression of [MAPK9](http://www.ensembl.org/id/ENSG00000050748). For a full overview of the Lung Adenocarcinoma (LUAD) miRNAs-lncRNAs-mRNAs network, please report to Li et al. [Figure 2](#ijms-21-03580-f002){ref-type="fig"} \[[@B161-ijms-21-03580]\].⋄**MEG3 at the clinical level:** MEG3 low-expression in NSCLC tumor tissues was associated with short-term survival in two independent public datasets \[[@B106-ijms-21-03580]\]. Besides, MEG3 genotype rs4081134 SNP (AA) was associated with a lung cancer risk in Chinese patients \[[@B85-ijms-21-03580]\]. While being promising, these findings should, however, be confirmed in additional large independent cohorts to classify MEG3 as a reliable biomarker.⋄**MEG3 behavior against treatment:** MEG3 can promote NSCLC cell lines sensitivity (A549 and H292) to Vincristine, by inhibiting autophagy. Indeed, autophagy level was higher in resistant cells, and the overexpression of MEG3 significantly reduced the expression of autophagy-related proteins LC3-I ([MAP1LC3A](http://www.ensembl.org/id/ENSG00000101460)), and LC3-II ([MAP1LC3B](http://www.ensembl.org/id/ENSG00000140941)) were \[[@B120-ijms-21-03580]\]. The overexpression of MEG3 can also increase the DDP-sensitivity of NSCLC cell lines (A549 and H1299) \[[@B117-ijms-21-03580]\] and xenografts \[[@B118-ijms-21-03580]\] by decreasing TP53, CTNNB1, survivin ([BIRC5](http://www.ensembl.org/id/ENSG00000130816)), therefore targeting the WNT/$\beta$-catenin signaling pathway \[[@B118-ijms-21-03580]\], and Bcl-xl ([BCL2L1](http://www.ensembl.org/id/ENSG00000171552)) \[[@B119-ijms-21-03580]\]. Furthermore, in Xu et al., the authors showed that Paclitaxel (PTX) could upregulate MEG3 and TP53, thus inhibiting cell proliferation and promoting the death of A549 cells \[[@B162-ijms-21-03580]\].⋄**Exosomal MEG3:** From the PubMed screening, we found no studies on MEG3 associated with lung diseases and exosomes. However, three recent studies could describe exosomal MEG3 in high-grade serous carcinoma \[[@B163-ijms-21-03580]\], cervical cancer \[[@B164-ijms-21-03580]\], and Hunner-type interstitial cystitis \[[@B165-ijms-21-03580]\]. These studies underline that MEG3 may be involved in intercellular communication, especially in cancers, and therefore further research on this topic is needed to assess its relevance in lung diseases.

2.3. MALAT1 {#sec2dot3-ijms-21-03580}
-----------

Metastasis Associated Lung Adenocarcinoma Transcript 1 ([MALAT1](http://www.ensembl.org/id/ENSG00000251562)) is an RNA gene localized on the cytogenetic band 11q13.1. MALAT1 gene has 17 transcripts, all identified as lncRNAs. MALAT1 may also act as a transcriptional regulator for numerous genes and is involved in the cell cycle regulation and pre-mRNA splicing \[[@B166-ijms-21-03580]\].

### 2.3.1. MALAT1 and Asthma {#sec2dot3dot1-ijms-21-03580}

In Zhu et al. RNA sequencing data, MALAT1 was observed as upregulated in the blood of highly-expressed IgE eosinophilic asthmatic (EA) patients when compared to healthy patients \[[@B61-ijms-21-03580]\]. The authors denoted the [T cell receptor signaling](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04660) as one of the main pathways impaired in EA patients. Moreover, Qiu et al. heatmap ([Figure 2](#ijms-21-03580-f002){ref-type="fig"}A) displays MALAT1 as upregulated in CD4${}^{+}$ cells from asthmatic patients when compared to healthy patients \[[@B59-ijms-21-03580]\].

### 2.3.2. MALAT1 and COPD {#sec2dot3dot2-ijms-21-03580}

MALAT1 was found the most abundant lncRNA in whole blood cells from former and current smokers with COPD \[[@B167-ijms-21-03580]\].

### 2.3.3. MALAT1 and Lung Cancer {#sec2dot3dot3-ijms-21-03580}

MALAT1 has been described as upregulated in NSCLC tumor tissues and cell lines, and it regulates cell proliferation, migration, invasion, EMT and apoptosis, but also mesenchymal-epithelial transition (MET) \[[@B77-ijms-21-03580],[@B79-ijms-21-03580],[@B101-ijms-21-03580],[@B102-ijms-21-03580],[@B168-ijms-21-03580],[@B169-ijms-21-03580],[@B170-ijms-21-03580],[@B171-ijms-21-03580],[@B172-ijms-21-03580],[@B173-ijms-21-03580],[@B174-ijms-21-03580],[@B175-ijms-21-03580],[@B176-ijms-21-03580],[@B177-ijms-21-03580],[@B178-ijms-21-03580]\]. It is worth underlining that Ghafouri-Fard et al. summarized the studies of MALAT1 to a broader range of cancers in the Table 1 of their review \[[@B179-ijms-21-03580]\]. MALAT1 uses the following mechanisms, as summarized in [Figure 7](#ijms-21-03580-f007){ref-type="fig"}. ⋄**Regulators of MALAT1:** TDP-43 ([TARDBP](http://www.ensembl.org/id/ENSG00000120948)) can upregulate MALAT1 expression through direct interaction in NSCLC cell lines (A549 and YTLMC-9) \[[@B169-ijms-21-03580]\]. Moreover, in the tumor tissues of NSCLC female patients, [ESR2](http://www.ensembl.org/id/ENSG00000140009) can upregulate MALAT1 expression by binding to estrogen-response-element I and II on the proximal 2-kb region of MALAT1 promoter \[[@B172-ijms-21-03580]\]. Additionally, in the NSCLC cell line (A549), Oct3/4 ([POU5F1](http://www.ensembl.org/id/ENSG00000204531)) and [SP1](http://www.ensembl.org/id/ENSG00000185591) can increase MALAT1 expression by physically binding its promoter \[[@B178-ijms-21-03580],[@B180-ijms-21-03580]\]. Furthermore, in NSCLC cell lines (SPC-A1 and H1299) in vitro and in vivo, [TFAP2C](http://www.ensembl.org/id/ENSG00000087510) and ZEB1 can upregulate MALAT1 expression, leading to the sequestration of miR-200b, which, in turn, increases of E2F3 and ZEB1, creating, therefore, a positive feedback loop \[[@B181-ijms-21-03580]\]. Some miRNAs may also regulate MALAT1. Indeed, hsa-miR-142-3p can inhibit MALAT1 and WNT/$\beta$-catenin signaling pathway in NSCLC tumor tissues and H1299 cell lines \[[@B75-ijms-21-03580]\]. Moreover, hsa-miR-101-3p can inhibit MALAT1, BCL2, MMP9, PI3K ([PIK3CA](http://www.ensembl.org/id/ENSG00000121879)) expressions in NSCLC cell lines (H1299 and H520) \[[@B77-ijms-21-03580]\].⋄**MALAT1 regulated genes:** In NSCLC cell lines (A549 and H1299), MALAT1 can repress TP53 expression at the pre-mRNA level by binding a responsive region in the TP53 P1 promoter, leading to the downregulation of CDKN1A and [FAS](http://www.ensembl.org/id/ENSG00000026103) expressions \[[@B170-ijms-21-03580]\]. In NSCLC cell lines (PC-9 and A549), MALAT1 also decreases cleaved-[PARP1](http://www.ensembl.org/id/ENSG00000143799), cleaved-CASP3, and upregulates phospho-STAT3 \[[@B171-ijms-21-03580]\], which in turn upregulates MDR1 ([ABCB1](http://www.ensembl.org/id/ENSG00000085563)) and MRP1 ([ABCC1](http://www.ensembl.org/id/ENSG00000103222)) \[[@B182-ijms-21-03580]\]. Moreover, MALAT1 is involved in the upregulation of BCL2, MMP9, PIK3CA expressions, thus activating the [PI3K/AKT signaling pathway](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04151) in NSCLC tumor tissues and H1299 cell lines \[[@B77-ijms-21-03580]\]. Furthermore, in NSCLC tumor tissues and cell lines (A549 and H1299), MALAT1 can upregulate VIM and downregulate CDH1 and is involved in the phosphorylation of [AKT1](http://www.ensembl.org/id/ENSG00000142208), [RPS6KB1](http://www.ensembl.org/id/ENSG00000108443), and [MTOR](http://www.ensembl.org/id/ENSG00000198793) \[[@B79-ijms-21-03580],[@B102-ijms-21-03580]\]. Besides, in NSCLC tumor tissues and cell lines (A549, H661, and H460), MALAT1 can upregulate [CXCL5](http://www.ensembl.org/id/ENSG00000163735), which in turn upregulates p-[MAPK8](http://www.ensembl.org/id/ENSG00000107643) and down-regulates p-[MAP2K1](http://www.ensembl.org/id/ENSG00000169032)/[2](http://www.ensembl.org/id/ENSG00000126934), p-MAPK3/1 proteins \[[@B176-ijms-21-03580],[@B183-ijms-21-03580]\].⋄**MALAT1 as ceRNA:** Among its known functions, MALAT1 was reported as a heavy miRNA regulator. Indeed, MALAT1 can sequester: • [hsa-miR-145](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000461) to release the expressions of [NEDD9](http://www.ensembl.org/id/ENSG00000111859) in the tumor tissues of NSCLC female patients \[[@B172-ijms-21-03580]\], and [KLF4](http://www.ensembl.org/id/ENSG00000136826) in NSCLC tumor tissues and cell lines (A549 and H1299) \[[@B184-ijms-21-03580]\] • [hsa-miR-204](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000284) to release the expression of [SNAI2](http://www.ensembl.org/id/ENSG00000019549) in NSCLC tumor tissues and cell lines (A549, H1299, H460, and H446) \[[@B185-ijms-21-03580]\] • [hsa-miR-124-1](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000443) to release the expression of STAT3 and [PI3K/AKT signaling pathway](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04151), in NSCLC cell lines (A549, H23, H522, H1299, H460) \[[@B78-ijms-21-03580]\] • [hsa-miR-206](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000490) and impact the [AKT/MTOR signaling pathway](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04150) in NSCLC tumor tissues and cell lines (A549 and H1299) \[[@B79-ijms-21-03580]\] • [hsa-miR-200b](http://www.mirbase.org/cgi-bin/mirna_entry?acc=MI0000342) to release [E2F3](http://www.ensembl.org/id/ENSG00000112242) and ZEB1 expressions, thus creating a positive feedback loop as ZEB1 can upregulate MALAT1 in NSCLC cell lines (SPC-A1 and H1299) in vitro and in vivo \[[@B181-ijms-21-03580]\] • [hsa-miR-200a-3p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000682) to release PD-L1 ([CD274](http://www.ensembl.org/id/ENSG00000120217)) expression in NSCLC tumor tissues and cell lines (A549 and CAL-12T) \[[@B186-ijms-21-03580]\] • [hsa-miR-429](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0001641) to release Cyclin D1 ([CCND1](http://www.ensembl.org/id/ENSG00000110092)), [MMP9](http://www.ensembl.org/id/ENSG00000100985), VIM, and CDH2 expression while repressing CDH1 expression in NSCLC tumor tissues \[[@B187-ijms-21-03580]\] • [hsa-miR-197-3p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000227) to release the Catenin-$\delta$1 ([CTNND1](http://www.ensembl.org/id/ENSG00000198561)) expression in NSCLC tumor tissues and cell lines (A549, H1299, H460 and SPC-A-1) \[[@B188-ijms-21-03580]\] • [hsa-miR-101-3p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000099) to release the expressions of [MCL1](http://www.ensembl.org/id/ENSG00000143384) in NSCLC tumor tissues and cell lines ((A549, H1299, H469, SPC-A1) \[[@B103-ijms-21-03580]\], and [SOX9](http://www.ensembl.org/id/ENSG00000125398) in NSCLC tumor tissues and cell lines (A549, H1299, HCC827, and H358) \[[@B76-ijms-21-03580]\]. Moreover, in NSCLC tumor tissues and cell lines (A549, H1299, HCC827, and H358), SOX9 could activate MALAT1 expression by binding MALAT1 promoter on a specific site (5′-TCATTGTGT-3′), thus creating a positive feedback loop which dramatically increases MALAT1 downstream effects. Besides, SOX9 contributes to the upregulation of CTNNB1, a downstream target of MYC, thus activating the WNT/$\beta$-catenin signaling pathway \[[@B76-ijms-21-03580]\].⋄**MALAT1 at the clinical level:** Several studies described a high MALAT1 level associated with a poor prognosis and short OS in NSCLC tumor tissues \[[@B76-ijms-21-03580],[@B79-ijms-21-03580],[@B101-ijms-21-03580],[@B102-ijms-21-03580],[@B103-ijms-21-03580],[@B105-ijms-21-03580]\]. Besides, MALAT1 level was low in the serum of patients with NSCLC; however, it still lacks some specificity \[[@B90-ijms-21-03580],[@B91-ijms-21-03580],[@B92-ijms-21-03580],[@B93-ijms-21-03580]\]. Furthermore, both MALAT1 and SOX9 expressions were associated with age, tumor size, and TNM stage, making these two genes potential candidates for prognosis tools \[[@B76-ijms-21-03580],[@B79-ijms-21-03580],[@B104-ijms-21-03580]\].⋄**MALAT1 behavior against treatment:** High MALAT1 expression was associated with a DDP chemo-resistance in NSCLC tumor tissues \[[@B76-ijms-21-03580],[@B103-ijms-21-03580],[@B184-ijms-21-03580],[@B188-ijms-21-03580]\] and cell lines \[[@B182-ijms-21-03580]\]. Interestingly, a feedback loop between MALAT1 and SOX9 may amplify this resistance \[[@B76-ijms-21-03580]\]⋄**Exosomal MALAT1:** Exosomal MALAT1 (exo-MALAT1) was described as upregulated in the serum of 77 NSCLC patients, and its expression was related to tumor stage and lymphatic metastasis \[[@B174-ijms-21-03580]\]. While being a potential new biomarker for tumor stage diagnosis, further studies should be conducted on larger cohorts to confirm the predictive power of exo-MALAT1.

2.4. FENDRR {#sec2dot4-ijms-21-03580}
-----------

FOXF1 adjacent non-coding developmental regulatory RNA ([FENDRR](http://www.ensembl.org/id/ENSG00000268388)) is an RNA gene localized on the cytogenetic band 16q24.1. FENDRR gene has 14 transcripts, all identified as lncRNAs. This gene is transcribed bidirectionally with [FOXF1](http://www.ensembl.org/id/ENSG00000103241) on the opposite strand. FENDRR may bind the polycomb repressive complex 2 (PRC2) to promote the methylation of its targeted genes.

### 2.4.1. FENDRR and IPF {#sec2dot4dot1-ijms-21-03580}

FENDRR levels were low in fibrotic human lung cells and mouse primary lung fibroblasts. Interestingly, Huang et al. hypothesized that the TGFB1/SMAD3 signaling pathway might cause these low levels. Besides, FENDRR may inhibit fibroblast activation and reduces pulmonary fibrosis by capturing [ACO1](http://www.ensembl.org/id/ENSG00000122729), thus reducing the iron levels, and by sequestrating the profibrotic [hsa-miR-214](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000290) \[[@B64-ijms-21-03580]\].

### 2.4.2. FENDRR and Lung Cancer {#sec2dot4dot2-ijms-21-03580}

Several studies described FENDRR as downregulated in NSCLC tumor tissues and cell lines. They also found FENDRR within the top three lncRNA sharing high connectivity with differentially expressed protein-coding genes. Besides, network prediction algorithms associated FENDRR with vasculature development, cell surface receptor-linked signal transduction, cell proliferation, EMT, stemness, metastasis, and apoptosis \[[@B88-ijms-21-03580],[@B116-ijms-21-03580],[@B189-ijms-21-03580],[@B190-ijms-21-03580],[@B191-ijms-21-03580],[@B192-ijms-21-03580],[@B193-ijms-21-03580],[@B194-ijms-21-03580]\]. FENDRR uses the following mechanisms, as summarized in [Figure 8](#ijms-21-03580-f008){ref-type="fig"}. ⋄**Regulators of FENDRR:** Two studies described FENDRR as hypermethylated through a presumable involvement of EZH2. This hypermethylation could explain its downregulation in NSCLC tumor tissues and cell lines (Calu-1 and H1975) \[[@B193-ijms-21-03580],[@B194-ijms-21-03580]\].⋄**FENDRR regulated genes:** In NSCLC tumor tissues, FENDRR can specifically bind to the 3'UTR of ABCB1, thus blocking HuR ([ELAVL1](http://www.ensembl.org/id/ENSG00000066044)) binding to ABCB1 3'UTR, and therefore resulting in the decrease of ABCB1 expression \[[@B195-ijms-21-03580]\]. Besides, Xu et al. found a negative correlation between FENDRR and [ABCC10](http://www.ensembl.org/id/ENSG00000124574) expressions in NSCLC tumor tissues and cell lines (A549) \[[@B116-ijms-21-03580]\].⋄**FENDRR as ceRNA:** In NSCLC tumor tissues, cell lines (H1650, HCC827, A549, and H1975) and xenografts, FENDRR could also act as a miRNA regulator. Indeed, FENDRR can sequester [hsa-miR-761](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0003941) to release the expression of the metalloproteinase inhibitor [TIMP2](http://www.ensembl.org/id/ENSG00000035862) \[[@B189-ijms-21-03580],[@B196-ijms-21-03580]\]. Additionally, Liu et al. associated FENDRR to prognostic-significant ceRNA networks using TCGA-LUAD data. They also listed seven other molecules associated with these ceRNA networks; three mRNAs, [EPAS1](http://www.ensembl.org/id/ENSG00000116016), FOXF1, and [EDNRB](http://www.ensembl.org/id/ENSG00000136160), and four miRNAs, [hsa-miR-148a](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000253), [hsa-miR-195](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000489), hsa-miR-196b, and [hsa-miR-301b](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0005568)). For an exhaustive overview of their FENDRR centered lncRNA--miRNA--mRNA ceRNA network, please refer to [Figure 5](#ijms-21-03580-f005){ref-type="fig"} of their study \[[@B197-ijms-21-03580]\].⋄**FENDRR at the clinical level:** FENDRR low-expression in tumor tissues is strongly associated with TNM 1 stage in LUAD patients. Furthermore, when associated with [LINC00312](https://www.genenames.org/data/gene-symbolreport/#!/hgnc_id/6662), FENDRR showed a diagnostic value in detecting these LUAD patients \[[@B88-ijms-21-03580]\]. Nevertheless, to confirm the diagnostic power of FENDRR on the TNM 1 stage of LUAD patients, additional studies should be conducted on a broader spectrum of lung cancers, including different cancer subtypes and TNM stages.⋄**FENDRR behavior against treatment:** The low expression of FENDRR observed in NSCLC tumor tissues was correlated with chemo-resistance to DDP \[[@B116-ijms-21-03580]\]. However, additional studies are required to confirm this result.⋄**Exosomal FENDRR:** From the PubMed search, we found no studies associating FENDRR to exosomes. However, FENDRR is an important lncRNA that controls the occurrence of metastasis. Indeed, low FENDRR expression was associated with distant metastasis and allowed the downregulation of the metalloproteinase inhibitor TIMP2 by the lack of competition with hsa-miR-761. Therefore, the metalloproteinase can degrade the extracellular matrix (ECM) and facilitates tumor metastasis \[[@B196-ijms-21-03580]\]. It would, therefore, be interesting to seek for FENDRR in the extracellular vesicles of lung cancer associated with distant metastasis.

2.5. TUG1 {#sec2dot5-ijms-21-03580}
---------

Taurine Up-Regulated 1 ([TUG1](http://www.ensembl.org/id/ENSG00000253352)) is an RNA gene localized on cytogenetic band 22q12.2. TUG1 gene has 20 transcripts, all identified as lncRNAs. TUG1 interacts with the PRCs to regulate the transcription and may also act as a ceRNA targeting miRNAs.

### 2.5.1. TUG1 and Asthma {#sec2dot5dot1-ijms-21-03580}

In ASM of Sprague Dawley rats, [rat TUG1](http://www.ensembl.org/id/ENSRNOG00000051135) was described upregulated and release [rat Fgf1](http://www.ensembl.org/id/ENSRNOG00000013867) through rno-miR-590-5p sequestration, thus leading the increase of cell proliferation and migration \[[@B62-ijms-21-03580]\].

### 2.5.2. TUG1 and COPD {#sec2dot5dot2-ijms-21-03580}

Gu et al. found TUG1 as upregulated, in sputum and lung tissues from COPD patients with or without a smoking history. They also demonstrated that TUG1 releases the expression of [DUSP6](http://www.ensembl.org/id/ENSG00000139318) through the sequestration of [hsa-miR-145-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000437), thus contributing to the inhibition of inflammation and airway remodeling \[[@B71-ijms-21-03580]\]. Besides, in TGFB1 treated BEAS-2B and HFL1 cells, TUG1 could block cell proliferation through the inhibition of $\alpha$SMA ([ACTA2](http://www.ensembl.org/id/ENSG00000107796)) and fibronectin 1 ([FN1](http://www.ensembl.org/id/ENSG00000115414)) expressions \[[@B72-ijms-21-03580]\].

### 2.5.3. TUG1 and Lung Cancer {#sec2dot5dot3-ijms-21-03580}

TUG1 was the only lncRNA described as downregulated in NSCLC tumor tissues and upregulated in Small Cell lung cancer (SCLC) tissues and the serum of LUAD patients. Interestingly, TUG1 downregulation was significant in the tumor tissues of male donors only and was associated with Squamous Cell Carcinoma (SCC) and LUAD tumor subtypes. This decrease was, however, strongly and significantly correlated to GAS5 decrease in Female donors and combined tumors when compared to adjacent non-cancerous tissues (ANCTs) \[[@B95-ijms-21-03580]\]. Furthermore, few studies described TUG1 associated with cell proliferation, migration, invasion, apoptosis, and autophagy \[[@B198-ijms-21-03580],[@B199-ijms-21-03580],[@B200-ijms-21-03580]\]. It is worth underlining that Ghaforui-Fard et al. summarized the studies of TUG1 to a broader range of cancers in Table 1 of their review \[[@B198-ijms-21-03580]\]. TUG1 uses the following mechanisms, as summarized in [Figure 9](#ijms-21-03580-f009){ref-type="fig"}. ⋄**Regulators of TUG1:** Zhang et al. found that TP53 can regulate TUG1 expression in NSCLC tumor tissues and SPC-A1 cell line in vitro and in vivo \[[@B105-ijms-21-03580],[@B107-ijms-21-03580]\]. This result requires, however, an independent validation. **⋄ TUG1 regulated genes:** In NSCLC tumor tissues, TUG1 has been described to trans-downregulate the expression of Homeobox B7 ([HOXB7](http://www.ensembl.org/id/ENSG00000260027)), [CELF1](http://www.ensembl.org/id/ENSG00000149187), and EZH2 (PRC2 subunit). Moreover, TUG1 decrease was also significantly associated with the differential expression of the following target genes. In both LUAD and SCC, TUG1 downregulation was associated with the downregulation of ELAVL1, [PTBP1](http://www.ensembl.org/id/ENSG00000011304), [IGF2BP1](http://www.ensembl.org/id/ENSG00000159217), [IGF2BP2](http://www.ensembl.org/id/ENSG00000073792), [IGF2BP3](http://www.ensembl.org/id/ENSG00000136231), [PUM2](http://www.ensembl.org/id/ENSG00000055917), [TNRC6A](http://www.ensembl.org/id/ENSG00000090905), [DGCR8](http://www.ensembl.org/id/ENSG00000128191), [FMR1](http://www.ensembl.org/id/ENSG00000102081), [FXR1](http://www.ensembl.org/id/ENSG00000114416), [FUS](http://www.ensembl.org/id/ENSG00000089280), [MOV10](http://www.ensembl.org/id/ENSG00000155363), [ZC3H7B](http://www.ensembl.org/id/ENSG00000100403), [EWSR1](http://www.ensembl.org/id/ENSG00000182944), FUS-mutant, [SRSF1](http://www.ensembl.org/id/ENSG00000136450), [U2AF2](http://www.ensembl.org/id/ENSG00000063244), [UPF1](http://www.ensembl.org/id/ENSG00000005007), and TARDBP \[[@B95-ijms-21-03580]\]. It was otherwise associated with the upregulation of [HNRNPC](http://www.ensembl.org/id/ENSG00000092199) \[[@B95-ijms-21-03580]\]. Conversely, in SCLCs, TUG1 may silence [LIMK2](http://www.ensembl.org/id/ENSG00000182541) and BAX expression by interacting with EZH2 \[[@B86-ijms-21-03580],[@B105-ijms-21-03580],[@B107-ijms-21-03580],[@B108-ijms-21-03580],[@B198-ijms-21-03580],[@B199-ijms-21-03580],[@B200-ijms-21-03580]\].⋄**TUG1 recruits the PRC2:** In NSCLC tumor tissues, TUG1 can regulate CELF1 through PRC2 binding \[[@B108-ijms-21-03580]\], and may also recruit EZH2, which will then trimethylates H3K27 and repress HOXB7 \[[@B95-ijms-21-03580]\].⋄**TUG1 as ceRNA:** In NSCLC tumor tissues, cell lines (SPC-A1, NCI-H520, NCI-H520, NCI-H1299) and xenograft, Guo et al. found that TUG1 can sequester [hsa-miR-221](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000298), thus releasing the expression of PTEN \[[@B83-ijms-21-03580]\].⋄**TUG1 at the clinical level:** On the one hand, TUG1 was upregulated in the serum of LUAD patients when compared to healthy serums \[[@B86-ijms-21-03580],[@B198-ijms-21-03580]\]. On the other hand, TUG1 low expression in NSCLC tumor tissues was associated with a high TNM stage and a poor patient outcome \[[@B105-ijms-21-03580],[@B107-ijms-21-03580],[@B108-ijms-21-03580],[@B198-ijms-21-03580]\].⋄**TUG1 behavior against treatment:** The low expression of TUG1 observed in NSCLC cells was associated with chemo-resistance to DDP. When overexpressed, TUG1 promoted the sensitivity of NSCLC cells to DDP, leading to apoptosis, in vitro, and in vivo \[[@B83-ijms-21-03580]\].⋄**Exosomal TUG1:** From the PubMed search, we found no studies associating TUG1 with lung diseases and exosomes. However, two recent studies mentioned exosomal TUG1, in MCF-7 cells, the levels of TUG1 were moderately elevated in exosomes when compared to cells \[[@B201-ijms-21-03580]\], and TUG1 was up-regulated in the serum exosomes of colorectal cancer (CRC) patients \[[@B202-ijms-21-03580]\]. Besides, Guo et al. described TUG1 as ceRNA to [hsa-miR-221](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000298), which enables PTEN expression \[[@B83-ijms-21-03580]\]. Together, these results suggest that TUG1 may be involved in intercellular communication to synchronize cellular proliferation. Therefore, further research on this topic is needed to assess its relevance in lung cancers.

2.6. CDKN2B-AS1, ANRIL {#sec2dot6-ijms-21-03580}
----------------------

CDKN2B Antisense RNA 1 ([CDKN2B-AS1](http://www.ensembl.org/id/ENSG00000240498)), also called ANRIL, is an RNA gene localized on cytogenetic band 9p21.3. CDKN2B-AS1 gene has 28 transcripts, all identified as lncRNAs and with some of which can turn into circular RNAs \[[@B203-ijms-21-03580]\]. CDKN2B-AS1 is known to bind CBX7 (PRC1 subunit) and SUZ12 (PRC2 subunit) to repress the transcription of p15 ([CDKN2B](http://www.ensembl.org/id/ENSG00000147883)) \[[@B42-ijms-21-03580],[@B204-ijms-21-03580],[@B205-ijms-21-03580]\].

### 2.6.1. CDKN2B-AS1 and IPF {#sec2dot6dot1-ijms-21-03580}

In the peripheral blood of IPF patients, CDKN2B-AS1 is downregulated when compared to healthy controls. The adjacent gene, CDKN2A, is transcribed simultaneously with CDKN2B-AS1 and is also downregulated in IPF patients. Importantly, Du et al. described that both CDKN2B-AS1 and CDKN2A might regulate the [TP53 signaling pathway](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04115) \[[@B63-ijms-21-03580]\]. Indeed, the CDKN2A protein is known to stabilize TP53 in NSCLC \[[@B206-ijms-21-03580]\], and the authors found the p53-signaling pathway as the top target gene-associated pathway in IPF patients.

### 2.6.2. CDKN2B-AS1 and Asthma {#sec2dot6dot2-ijms-21-03580}

In their study on bronchial asthma at exacerbation (BA-E) and bronchial asthma at remission (BA-R), Ye et al. described CDKN2B-AS1 as upregulated in the plasma of patients with both types of bronchial asthma when compared to healthy subjects. Moreover, CDKN2B-AS1 is upregulated in BA-E patients when compared to BA-R patients. These authors also found a negative correlation between CDKN2B-AS1 and [hsa-miR-125a](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000469) in all patients, suggesting miRNA sequestration. In [Table 2](#ijms-21-03580-t002){ref-type="table"} and [Table 3](#ijms-21-03580-t003){ref-type="table"} from the same study, the authors found CDKN2B-AS1 negatively correlated with FEV_1/FVC in BA-E patients, and positively correlated with pro-inflammatory cytokines, such as TNF in BA-E patients and IL17A in both BA-E and BA-R patients \[[@B58-ijms-21-03580]\].

### 2.6.3. CDKN2B-AS1 and COPD {#sec2dot6dot3-ijms-21-03580}

Ge et al. described CDKN2B-AS1 as downregulated in the plasma from acute exacerbations of COPD (AECOPD) when compared to stable COPD or healthy patients. These authors also found a negative correlation between the expression of CDKN2B-AS1 and inflammatory cytokines such as TNF, IL1B, IL17A, and Leukotriene B4 (LTB4) in both AECOPD and stable COPD patients. Furthermore, they found another negative correlation between CDKN2B and IL8 ([CXCL8](http://www.ensembl.org/id/ENSG00000169429)) only in AECOPD patients \[[@B67-ijms-21-03580]\].

### 2.6.4. CDKN2B-AS1 and Lung Cancer {#sec2dot6dot4-ijms-21-03580}

CDKN2B-AS1 was described as upregulated in NSCLC tumor tissues and cell lines and was among the top three lncRNAs with high connectivity with differentially expressed protein-coding genes \[[@B87-ijms-21-03580],[@B88-ijms-21-03580],[@B207-ijms-21-03580]\]. CDKN2B-AS1 high expression is also known to promote cell proliferation, cell migration, and to be involved in apoptosis \[[@B208-ijms-21-03580],[@B209-ijms-21-03580]\]. CDKN2B-AS1 uses the following mechanisms, as summarized in [Figure 10](#ijms-21-03580-f010){ref-type="fig"}. ⋄**Regulators of CDKN2B-AS1:** In NSCLC tumor tissues and cell lines (A549, SPC-A1, and NCI-H1975), MYC can upregulate CDKN2B-AS1 by physically interacting with the c-Myc-responsive element (E-box) of CDKN2B-AS1 promoter \[[@B87-ijms-21-03580],[@B208-ijms-21-03580]\]. Besides, Midkine ([MDK](http://www.ensembl.org/id/ENSG00000110492)) was described as often upregulated in the tumor microenvironment of SCC tumor tissues and cell lines (SCC4, OSCC3, HSC3, and CAL27). The authors also found that MDK can upregulate the CDKN2B-AS1 expression \[[@B121-ijms-21-03580]\].⋄**DKN2B-AS1 regulated genes:** In NSCLC tumor tissues, Alsibai et al. found a strong positive correlation between the expressions of CDKN2B-AS1 and the tumor suppressors p15-CDKN2B and p14-CDKN2A, but not p16-CDKN2A. Interestingly, expressed CDKN2B-AS1 can stabilize the PRC complexes to repress the expression of p15, p14, and p16, leading to activate the cell cycle \[[@B207-ijms-21-03580]\]. Few additional studies described the ability of CDKN2B-AS1 to decrease the expression of PARP1, cleaved-PARP1, and cleaved-CASP3, and to increase BCL2 and CASP3 expressions \[[@B87-ijms-21-03580],[@B121-ijms-21-03580]\].⋄**CDKN2B-AS1 recruits the PRC2:** CDKN2B-AS1 can also silence [KLF2](http://www.ensembl.org/id/ENSG00000127528) and CDKN1A transcription by binding with EZH2 in NSCLC tumors tissues and cell lines (PC9, SPC-A1, NCI-H1975, H1299, H358 and (H520) \[[@B209-ijms-21-03580]\].⋄**CDKN2B-AS1 at the clinical level:** Lin et al. found a positive correlation between CDKN2B-AS1 high-expression and the differentiation grade and TNM stages in LUAD \[[@B87-ijms-21-03580]\]. CDKN2B-AS1 high-expression in NSCLC tumor tissues was also associated with poor patient OS \[[@B94-ijms-21-03580]\]. Intriguing results from Du et al. suggested that a low CDKN2B-AS1 expression in the peripheral blood of IPF patients may promote the occurrence of lung cancers by regulating the P53 signaling pathway \[[@B63-ijms-21-03580]\]. However, further investigations should be conducted on IPF patients that developed lung cancer to confirm this hypothesis. Interestingly, CDKN2B-AS1 SNPs were strongly associated with the risk of developing a LUAD \[[@B210-ijms-21-03580],[@B211-ijms-21-03580],[@B212-ijms-21-03580],[@B213-ijms-21-03580],[@B214-ijms-21-03580]\].⋄**CDKN2B-AS1 behavior against treatment:** CDKN2B-AS1 high expression increases PTX resistance of A549 cells \[[@B87-ijms-21-03580]\]. Interestingly, Zhang et al. showed that cancer-associated fibroblasts (CAFs) contribute to the high level of MDK in the tumor micro-environment of Oral Squamous Cell Carcinoma (OSCC) tissues, thus promoting a DDP resistance via a high expression of CDKN2B-AS1 \[[@B121-ijms-21-03580]\].⋄**Exosomal CDKN2B-AS1:** From the PubMed search, we did not find studies associating CDKN2B-AS1 with lung diseases and exosomes. Moreover, only one recent study mentioned exosomal CDKN2B-AS1 as significantly higher in the urine of BC patients when compared to healthy subjects \[[@B215-ijms-21-03580]\]. However, CDKN2B-AS1 is an important lncRNA that can decrease the expression levels of PARP1, which plays a crucial role in DNA repair \[[@B87-ijms-21-03580],[@B121-ijms-21-03580]\]. Since the alteration of the DNA repair mechanism is part of the hallmark of cancers, it would be interesting to seek for CDKN2B-AS1 in the extracellular vesicles of early-stage lung tumors.

2.7. HOTAIR {#sec2dot7-ijms-21-03580}
-----------

HOX Transcript Antisense RNA ([HOTAIR](http://www.ensembl.org/id/ENSG00000228630)) is an RNA gene localized on the cytogenetic band 12q13.13. HOTAIR gene has five transcripts, all identified as lncRNAs.

### 2.7.1. HOTAIR and COPD {#sec2dot7dot1-ijms-21-03580}

In Male BALB/c mice exposed for four days with CS as well as human bronchial epithelial (HBE) cells treated with CSE, STAT3 activation led to the upregulation of HOTAIR and EZH2. Additionally, the levels of inflammatory factors, IL6 and CXCL8, as well as the EMT markers, CDH2, VIM, and ACTA2, increased, while CDH1 levels decreased. Nevertheless, these results shall be confirmed in COPD patients \[[@B69-ijms-21-03580]\].

### 2.7.2. HOTAIR and Lung Cancer {#sec2dot7dot2-ijms-21-03580}

In Nakagawa et al.'s study on NSCLC tumor tissues, 22.1% of the patients showed at least a two-fold increased expression of HOTAIR. This increase was more frequent in patients with an advanced stage of the tumor than in patients with other stages \[[@B98-ijms-21-03580]\]. Furthermore, HOTAIR expression could upregulate cell migration and anchorage-independent cell growth \[[@B87-ijms-21-03580],[@B98-ijms-21-03580],[@B146-ijms-21-03580]\]. Under hypoxic conditions, HOTAIR also enhances cell proliferation, migration, invasion, EMT, the formation of cancer stem cells (CSCs), and inhibits G0/G1 cell-cycle arrest and cell apoptosis \[[@B73-ijms-21-03580],[@B112-ijms-21-03580],[@B216-ijms-21-03580],[@B217-ijms-21-03580],[@B218-ijms-21-03580]\]. More generally, the HOX cluster-embedded lncRNAs (HOX-lncRNAs) plays a significant role in the regulation of their adjacent coding genes and several HOX-lncRNAs, including [HOTTIP](http://www.ensembl.org/id/ENSG00000243766), [HOXA11-AS](http://www.ensembl.org/id/ENSG00000240990), [HOTAIRM1](http://www.ensembl.org/id/ENSG00000233429), [HOXA-AS3](http://www.ensembl.org/id/ENSG00000254369), [HOXA10-AS](http://www.ensembl.org/id/ENSG00000253187), HOTAIR, and [HAGLR](http://www.ensembl.org/id/ENSG00000224189), which are dysregulated in lung cancer \[[@B218-ijms-21-03580]\]. HOTAIR uses the following mechanisms, as summarized in [Figure 11](#ijms-21-03580-f011){ref-type="fig"}. ⋄**Regulators of HOTAIR:** In the NSCLC cell line A549, HOTAIR was described as upregulated by hypoxia and CSE \[[@B216-ijms-21-03580],[@B217-ijms-21-03580]\], and is a direct target of HIF-1$\alpha$ ([HIF1A](http://www.ensembl.org/id/ENSG00000100644)), which acts through interaction with putative hypoxia-responsive elements (HREs) in the upstream region of HOTAIR \[[@B216-ijms-21-03580]\]. Besides, pro-inflammatory IL6 can activate STAT3 in an autocrine path, and STAT3 will then increase HOTAIR expression by interacting with its promoter \[[@B217-ijms-21-03580]\]. In NSCLC tumor tissues and A549 cell line, Caveolin 1 ([CAV1](http://www.ensembl.org/id/ENSG00000105974)) was described to upregulate HOTAIR \[[@B219-ijms-21-03580]\]. Interestingly, a specific negative regulation loop involves HOTAIR and TP53 in NSCLC tumor tissues. Indeed, two TP53 binding sites were found on HOTAIR's promoter and can suppress HOTAIR transcription after TP53 binding. HOTAIR can, in turn, modify the promoter of TP53 by increasing H3K27me3 leading to TP53 repression \[[@B220-ijms-21-03580]\].⋄**HOTAIR regulated genes:** In SCLC cell lines (H69 and H446), HOTAIR can activate the NF-κB signaling pathway through the methylation of [HOXA1](http://www.ensembl.org/id/ENSG00000105991) \[[@B73-ijms-21-03580]\]. Indeed, HOTAIR regulates the HOXA1 methylation level by decreasing DNMT1 and DNMT3B expression \[[@B115-ijms-21-03580]\]. In an NSCLC cell line (PC9), HOTAIR is involved in cellular growth with p65 ([RELA](http://www.ensembl.org/id/ENSG00000173039)), DNMT1, and EZH2. Moreover, HOTAIR can inhibit JUN and CDKN1A \[[@B221-ijms-21-03580]\]. Furthermore, in NSCLC tumors tissues and PC9 cell line, HOTAIR can activate [WNT3A](http://www.ensembl.org/id/ENSG00000154342), CTNNB1, [APC](http://www.ensembl.org/id/ENSG00000134982), ABCC1, and ABCB1, and can also promote the expression of 14-3-3$\sigma$ ([SFN](http://www.ensembl.org/id/ENSG00000175793)) \[[@B222-ijms-21-03580],[@B223-ijms-21-03580]\]. In NSCLC tumor tissues and A459 cell line, HOTAIR would also upregulate CSC-related biomarkers such as [NANOG](http://www.ensembl.org/id/ENSG00000111704), POU5F1, SOX2, MYC, CTNNB1, and KLF4 \[[@B113-ijms-21-03580]\]. In NSCLC tumor tissues and cell lines (A549, PC9, H1299, and H520), Besides, HOTAIR was associated with LSH ([HELLS](http://www.ensembl.org/id/ENSG00000119969)) to regulate the [FOXA1](http://www.ensembl.org/id/ENSG00000129514) to [FOXA2](http://www.ensembl.org/id/ENSG00000125798) ratio and promote cell migration and invasion. Importantly, HELLS regulates this ratio by binding to the promoter of FOXA1, not FOXA2 \[[@B224-ijms-21-03580]\]. Additionally, in Lung cancer cell lines (A549, H460, H1299, NCI-H460, HCC-827), HOTAIR regulates the expression of [BECN1](http://www.ensembl.org/id/ENSG00000126581), phospho-[ULK1](http://www.ensembl.org/id/ENSG00000177169), and the LC3II/I (MAP1LC3A / [MAP1LC3B](http://www.ensembl.org/id/ENSG00000140941)) ratio \[[@B81-ijms-21-03580]\].⋄**HOTAIR recruits the PRC2:** Fang et al. recently described a negative feedback regulator loop involving HOTAIR in SCLC cell lines (NCI-H69 and NCI-H446). Indeed, HOTAIR may upregulate EZH2 and H3K27me3 levels, which in turn can repress HOTAIR, leading to change HOXA1 methylation \[[@B225-ijms-21-03580]\]. Interestingly, both HOTAIR 5' and 3' ends may be involved in the cell cycle dysregulation. Indeed, in NSCLC cell lines (95C, 95D, and YTMLC-90), Liu et al. demonstrated that RB1 and E2F1 are both regulated by HOTAIR5' via the PRC2 (EZH2, SUZ12, and EED) complex and by HOTAIR3' via the [LSD1](http://www.ensembl.org/id/ENSG00000004487)/ [CoREST](http://www.ensembl.org/id/ENSG00000089902)/ [REST](http://www.ensembl.org/id/ENSG00000084093) complex. Both complexes may, therefore, act on the WNT/$\beta$-catenin signaling pathway and promote EMT when coupled with histone H3 lysine 27 methylation and lysine 4 demethylation \[[@B80-ijms-21-03580]\].⋄**HOTAIR as ceRNA:** Among its known functions, HOTAIR was reported as a miRNA regulator. Indeed, HOTAIR can sequester: • [hsa-miR-214-3p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000271) to release the expression of [PDPK1](http://www.ensembl.org/id/ENSG00000140992), in NSCLC cell lines (A549 and PC9 cells) \[[@B226-ijms-21-03580]\] • [hsa-miR-217](http://www.mirbase.org/cgi-bin/mature.pl?acc=MI0000293) to release the expression of [DACH1](http://www.ensembl.org/id/ENSG00000276644), in NSCLC cell lines (H23, H292, H1299, and A549) \[[@B227-ijms-21-03580]\] • [hsa-miR-326](http://www.mirbase.org/cgi-bin/mature.pl?acc=MI0000808) to release the expression of SP1, in NSCLC tumor tissues and A549 cell line \[[@B228-ijms-21-03580]\], and [PHOX2A](http://www.ensembl.org/id/ENSG00000165462) in NSCLC cell lines (A549, 95D, NCI-H460, HLamp, and H838) \[[@B229-ijms-21-03580]\]. HOTAIR may also sequester [hsa-miR-613](http://www.mirbase.org/cgi-bin/mature.pl?acc=MI0003626) in NSCLC tumor tissues and cell lines (H1299, H23, H292, and A549) \[[@B230-ijms-21-03580]\], and hsa-miR-221 in NSCLC tumor tissues and cell lines (A549, H322, and H1299) \[[@B100-ijms-21-03580]\].⋄**HOTAIR at the clinical level:** HOTAIR high expression in NSCLC tumor tissues coincides with greater tumor size, advanced TNM stage, lymph node metastasis or lymph-vascular invasion, and short disease-free interval \[[@B98-ijms-21-03580]\]. Its expression was also related to a reduced OS in NSCLC tumor tissues \[[@B99-ijms-21-03580]\]. Furthermore, the expressions of HOTAIR in patients with stage I and II were lower than those with stage III and IV NSCLC tumors \[[@B100-ijms-21-03580]\]. Besides, both H19 and HOTAIR were identified as non-invasive diagnostic biomarkers in the sputum of lung cancer patients \[[@B109-ijms-21-03580]\]. The diagnosis of head-and-neck squamous cell carcinoma (HNSCC) can also be improved by combining the high expression of HOTAIR to the high expression of [CASC9](http://www.ensembl.org/id/ENSG00000249395) \[[@B231-ijms-21-03580]\]. Altogether, these encouraging results underline the potential of HOTAIR as a diagnostic biomarker.⋄**HOTAIR behavior against treatment:** HOTAIR high-expression contributes to DDP resistance via CDKN1A downregulation in LUAD tumor tissues, and experimental downregulated HOTAIR in A549 cells promoted DDP sensitivity \[[@B112-ijms-21-03580],[@B113-ijms-21-03580]\]. It also contributes to Atractylenolide 1 and Erlotinib resistances by activating PDK1 and EZH2, in LUAD cells, in vitro and in vivo \[[@B114-ijms-21-03580]\]. Besides, the downregulation of HOTAIR can increase the SCLC cell lines' sensitivity to DDP, Adriamycin, and Etoposide, through decreasing DNMT1 and DNMT3B expressions, leading to the reduction of HOXA1 methylation \[[@B115-ijms-21-03580]\]. Furthermore, the downregulation of HOTAIR can increase NSCLC cell lines sensitivity (A549, H460, H1299, NCI-H460, HCC-827) to Crizotinib through the inhibition of ULK1-phosphorylation. This sensitivity leads to the suppression of tumor growth and triggers the cell cycle arrest and the [apoptosis signaling pathway](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04210) \[[@B81-ijms-21-03580]\].⋄**Exosomal HOTAIR:** Exosomal HOTAIR (exo-HOTAIR) appeared in the exosomes from bronchoalveolar lavage (BAL) of smokers, NSCLC, and healthy patients, but without significant differences between the three conditions \[[@B232-ijms-21-03580]\]. However, in a recent letter to editors, Zhang et al. found exo-HOTAIR more expressed in the blood samples from LCC patients when compared to LUAD or SCC patients. Moreover, these authors described that A549 and H1299 cells treated with exo-HOTAIR increased the level of cellular HOTAIR. The authors concluded that exo-HOTAIR promotes proliferation, migration, and invasion of the cells through the sequestration of hsa-miR-203 ([hsa-mir-203a](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000283) or [hsa-mir-203b](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0017343)) \[[@B233-ijms-21-03580]\]. Interestingly, this interaction between hsa-miR-203 and HOTAIR was also reported with similar effects in renal cell carcinoma cells. In this study, Dasgupta et al. described that the sequestration of hsa-miR-203 decreases CDH1, PTEN, CDKN1A, and CDKN1B levels, while it increases the expression of VIM \[[@B234-ijms-21-03580]\].

2.8. GAS5 {#sec2dot8-ijms-21-03580}
---------

Growth Arrest Specific 5 ([GAS5](http://www.ensembl.org/id/ENSG00000234741)) is an RNA gene localized on the cytogenetic band 1q25.1. GAS5 gene has 31 transcripts, 20 identified as retained introns, and 11 identified as lncRNAs. GAS5 can bind the DNA binding domain of the glucocorticoid receptor, which disable it from regulating the transcription of its target genes.

### 2.8.1. GAS5 and Asthma {#sec2dot8dot1-ijms-21-03580}

In Qiu et al. study, the heatmap [Figure 2](#ijms-21-03580-f002){ref-type="fig"}A displays an upregulated GAS5 in CD4${}^{+}$T-cells from patients with severe asthma vs. healthy patients, with a fold change greater than 2 \[[@B59-ijms-21-03580]\]. These results add to Keenan et al. previous observations in bronchial epithelial cells (BEAS-2B) and primary human airway smooth muscle (ASM) cultures. Indeed, pro-inflammatory mediators, TNF, and IL1$\alpha$ ([IL1A](http://www.ensembl.org/id/ENSG00000115008)) were observed to promote GAS5 upregulation in ASM and BEAS-2B cells, which in turn can modulate glucocorticoid activity and thus may mediate glucocorticoid insensitivity \[[@B60-ijms-21-03580]\].

### 2.8.2. GAS5 and Lung Cancer {#sec2dot8dot2-ijms-21-03580}

GAS5 expression levels are low in lung cancers. Interestingly, this decrease in NSCLC is significant in male donors only \[[@B95-ijms-21-03580]\]. GAS5 is involved in cellular proliferation, metastasis, and autophagy. GAS5 uses the following mechanisms, as summarized in [Figure 12](#ijms-21-03580-f012){ref-type="fig"}. ⋄**GAS5 regulated genes:** In NSCLC tumor tissues, GAS5 decrease correlates strongly and significantly to the decrease of [FAS-AS1](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/37128) and [THRIL](http://www.ensembl.org/id/ENSG00000280634) in male donors and combined tumors, as well as the increase of [NEAT1](http://www.ensembl.org/id/ENSG00000245532) in male donors and combined tumors. GAS5 decrease also correlates with [TUG1](http://www.ensembl.org/id/ENSG00000253352) increase in female donors and combined tumors, and with [PVT1](http://www.ensembl.org/id/ENSG00000249859) increase in female donors when compared to ANCTs. GAS5 expression is also associated with the upregulation of IGF2BP2 and the downregulation of FXR1 \[[@B95-ijms-21-03580]\]. Moreover, GAS5 downregulates the expression of TNRC6A, ZC3H7B, and UPF1, while it can upregulate the expression of [EIF4A3](http://www.ensembl.org/id/ENSG00000141543), [TIA1](http://www.ensembl.org/id/ENSG00000116001), [TIAL1](http://www.ensembl.org/id/ENSG00000151923), and HNRNPC \[[@B95-ijms-21-03580]\]. Besides, in NSCLC tumor tissues and cell lines (A549, H1299, H1975, HCC827), GAS5 can deregulate the expression of phospho-EGFR, phospho-MAPK1, phospho-AKT1, and [IGF1R](http://www.ensembl.org/id/ENSG00000140443). Interestingly, GAS5 overexpression inversely correlates with the activation of the [EGFR pathway](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa01521) \[[@B110-ijms-21-03580]\].⋄**GAS5 as ceRNA:** Among its known functions, GAS5 can act as a miRNA regulator. Indeed, GAS5 may sequester hsa-miR-21-5p in NSCLC tumor tissues and the cell lines (NCI-H460, A549, NCI-H1299, H460, SK-MES-1, H157, and H358) \[[@B82-ijms-21-03580],[@B111-ijms-21-03580]\]. GAS5 may also sequester hsa-miR-205-5p in the NSCLC cell lines (A549, H460, 95D, H1299, SPC-A-1, and H522) \[[@B235-ijms-21-03580]\]. Both hsa-miR-21-5p and hsa-miR-205-5p sequestration would release the expression of PTEN \[[@B82-ijms-21-03580],[@B111-ijms-21-03580],[@B235-ijms-21-03580]\]. Additionally, GAS5 suspected of sequestering [hsa-miR-135b-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000758) in NSCLC tumor tissues and cell lines (A549 and H1975) \[[@B236-ijms-21-03580]\]. It is also suspected to sequester [hsa-miR-23a](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000079) in NSCLC tumor tissues and cell lines (A549, H838, H157, and HCC827) \[[@B237-ijms-21-03580]\].⋄**GAS5 at the clinical level:** Esfandi et al. emphasized the GAS5 low expression in tumor tissues as a promising biomarker for the diagnosis of the NSCLCs \[[@B95-ijms-21-03580]\].⋄**GAS5 behavior against treatment:** GAS5 may regulate chemo-resistance to DDP of NSCLC tumor tissues and cell lines (H460 and H157), through the [PTEN signaling pathway](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04151) \[[@B82-ijms-21-03580]\]. Besides, GAS5 low expression contributes to resistance to gefitinib to LUAD cell lines and tumor tissues \[[@B110-ijms-21-03580]\]. Furthermore, its low expression can promote the resistance to ionizing radiation in NSCLC cell lines \[[@B111-ijms-21-03580]\] and tumor tissues \[[@B236-ijms-21-03580]\].⋄**Exosomal GAS5:** In Cheng et al. study on urethane-induced lung cancer mouse model, lung cancer-derived exosomal GAS5 (exo-GAS5) affects the proliferation, apoptosis, and tube formation of human umbilical vein endothelial cells (HUVECs). The overexpression of GAS5 leads to an increase of exo-GAS5, upregulates PTEN expression, and inhibits the phosphorylation of PI3K/AKT, through hsa-miR-29b-3p sequestration \[[@B238-ijms-21-03580]\]. Furthermore, exo-GAS5 expression was lower in the serum of 64 NSCLC patients when compared to healthy controls. This low expression of exo-GAS5 was associated with larger tumor size and advanced TNM \[[@B239-ijms-21-03580]\]. While being a potential new biomarker for the diagnosis of Stage I NSCLCs, further studies should be conducted on larger cohorts to confirm the predictive power of exo-GAS5.

3. Additional LncRNAs Not Yet Described in Lung Cancer Studies {#sec3-ijms-21-03580}
==============================================================

3.1. LINC00861 {#sec3dot1-ijms-21-03580}
--------------

Long Intergenic Non-Protein Coding RNA 861 ([LINC00861](http://www.ensembl.org/id/ENSG00000245164)) is an RNA gene localized on the cytogenetic band 8q24.13. LINC00861 gene has 9 transcripts, all identified as lncRNAs.

### 3.1.1. LINC00861 in Asthma {#sec3dot1dot1-ijms-21-03580}

In RNAseq available data, LINC00861 transcript 201 ([LINC00861-201](http://www.ensembl.org/id/ENST00000500989)) was found upregulated in eosinophilic asthma and eosinophilic asthma with high Igg patients vs. healthy patients \[[@B61-ijms-21-03580]\].

### 3.1.2. LINC00861 in COPD {#sec3dot1dot2-ijms-21-03580}

In COPD smokers, LINC00861 expression is lower than in non-smoking COPD or healthy patients. LINC00861 and the uncharacterized LOC101928100 RNA gene were co-expressed with [RORA](http://www.ensembl.org/id/ENSG00000069667), while the authors observed an upregulation of [hsa-miR-218-5p](http://www.mirbase.org/cgi-bin/mature.pl?acc=MIMAT0000275). The authors hypothesized that the LINC00861/LOC101928100 upregulation releases the expression of RORA through the sequestration of both hsa-miR-218-5p and [hsa-miR-15a](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000069) \[[@B240-ijms-21-03580]\].

3.2. CCDC18-AS1, RP4-717I23.3 {#sec3dot2-ijms-21-03580}
-----------------------------

[CCDC18-AS1](http://www.ensembl.org/id/ENSG00000223745) is an RNA gene localized on the cytogenetic band 1p22.1. CCDC18-AS1 gene has 32 transcripts, all identified as lncRNAs.

### 3.2.1. CCDC18-AS1 in Asthma {#sec3dot2dot1-ijms-21-03580}

In asthma and severe asthma when compared to healthy controls, CCDC18-AS1 was upregulated, as shown by [Figure 2](#ijms-21-03580-f002){ref-type="fig"}B of Chen et al. study \[[@B241-ijms-21-03580]\].

### 3.2.2. CCDC18-AS1 in COPD {#sec3dot2dot2-ijms-21-03580}

In PBMCs of COPD smokers, CCDC18-AS1 transcripts ([CCDC18-AS1-220](http://www.ensembl.org/id/ENST00000452347.6) and [CCDC18-AS1-214](http://www.ensembl.org/id/ENST00000445076.2)) are upregulated when compared with COPD nonsmokers \[[@B242-ijms-21-03580]\].

4. Additional Interesting Exosomal-LncRNAs Described with Lung Cancer {#sec4-ijms-21-03580}
=====================================================================

4.1. Exo-UCA1 {#sec4dot1-ijms-21-03580}
-------------

Urothelial Cancer-Associated 1 ([UCA1](http://www.ensembl.org/id/ENSG00000214049)) is an RNA gene localized on the cytogenetic band 19p13.12. UCA1 has 45 known transcripts, all of them described as lncRNAs. UCA1 can promote cell proliferation and resistance to gefitinib-induced cell apoptosis. It can also sequester [miR-143](http://www.mirbase.org/cgi-bin/mirna_entry.pl?acc=MI0000459) to release [FOSL2](http://www.ensembl.org/id/ENSG00000075426) expression, leading to gefitinib resistance of epidermal growth factor receptor-positive (EGFR+) NSCLCs \[[@B243-ijms-21-03580]\].

**exo-UCA1 behavior against in lung cancer treatment** Kwok et al. demonstrated that the transfer of extracellular Vesicle-Associated-RNAs could induce drug resistance in ALK-Translocated lung Adenocarcinoma \[[@B244-ijms-21-03580]\]. Moreover, exo-UCA1 levels are high in both gefitinib-resistant NSCLC cells and their secreted exosomes \[[@B243-ijms-21-03580]\].

4.2. Exo-lncMMP2-2 {#sec4dot2-ijms-21-03580}
------------------

Wu et al. recently described exosomal [lnc-MMP2-2-1_dup1](http://www.noncode.org/show_rna.php?id=NONHSAT142627) could regulate migration and invasion of lung cancer cells to the vasculature by promoting [MMP2](http://www.ensembl.org/id/ENSG00000087245) expression \[[@B245-ijms-21-03580]\].

4.3. Exo-GAPLINC {#sec4dot3-ijms-21-03580}
----------------

Gastric Adenocarcinoma Associated, Positive CD44 Regulator, Long Intergenic Non-Coding RNA ([GAPLINC](http://www.ensembl.org/id/ENSG00000266835)) is an RNA gene localized on the cytogenetic band 18p11.31. GAPLINC has four transcripts, all described as lncRNAs. Exosomal GAPLINC (exo-GAPLINC), was described to promote erlotinib resistance in NSCLCs \[[@B246-ijms-21-03580]\]. Erlotinib is a tyrosine kinase inhibitor that is effective in patients with or without EGFR mutations but appears to be more effective in patients with EGFR mutations.

4.4. Exo-TBILA and Exo-AGAP2-AS1 {#sec4dot4-ijms-21-03580}
--------------------------------

TGF-Beta Induced lncRNA ([TBILA](http://www.ensembl.org/id/ENSG00000261488)) is an RNA gene localized on the cytogenetic band 3q13.2. AGAP2 Antisense RNA 1 ([AGAP2-AS1](http://www.ensembl.org/id/ENSG00000255737)) is an RNA gene localized on the cytogenetic band 12q14.1. Both TBILA and AGAP2-AS1 have a unique transcript identified as a lncRNA. Both exosomal TBILA (exo-TBILA) and exosomal AGAP2-AS1 (exo-AGAP2-AS1) expression are higher in the serum of NSCLC patients than in exosomes-depleted serum (EDS) from NSCLC patients or serum of healthy patients. Importantly, these two lncRNAs are very stable in the bloodstream, which makes them promising biomarkers. Moreover, they have only one known transcript each, which reduces potential screening errors. TBILA can discriminate all NSCLC patients, while AGAP2-AS1 is better as distinguishing SCC patients from healthy controls. Additionally, the authors mentioned that the combination of TBILA/AGAP2-AS1 with Cyfra21 ([KRT19](http://www.ensembl.org/id/ENSG00000171345)), a protein widely used in clinical practices, could distinguish all NSCLC patients from healthy controls in their study \[[@B247-ijms-21-03580]\].

4.5. Exo-SOX2-OT {#sec4dot5-ijms-21-03580}
----------------

SOX2 Overlapping Transcript ([SOX2-OT](http://www.ensembl.org/id/ENSG00000242808)) is an RNA gene localized on the cytogenetic band 3q26.33. SOX2-OT has 104 known transcripts, all identified as lncRNAs Exosomal [SOX2-OT](http://www.ensembl.org/id/ENSG00000242808) (exo-SOX2-OT) was significantly upregulated in Lung Squamous Cell Carcinoma (LSCC) patients when compared to non-LSCC patients. Exo-SOX2-OT levels in plasma correlated with tumor size and TNM stages, and might also reflect SOX2-OT expression in tumors \[[@B248-ijms-21-03580]\]. Nevertheless, with 104 known transcripts, all identified as lncRNAs, further studies should identify which transcripts are useful for diagnosis.

5. Concluding Remarks and Future Perspectives {#sec5-ijms-21-03580}
=============================================

LncRNAs are promising molecules for the better understanding of protein-gene regulations and subsequent pathways that define lung diseases. In the current review, we attempted to cover well-described lncRNAs associated with at least two lung diseases within asthma, IPF, COPD, and lung cancers. First, we searched into the PubMed database for publications related to lncRNAs in each of the four lung diseases. Secondly, we built and described the networks of molecular interactions of the lncRNAs H19, MALAT1, MEG3, FENDRR, CDKN2B-AS1, TUG1, HOTAIR, and GAS5, within each disease. Thirdly, we reported the clinical relevance of each of these lncRNAs, focusing on the biomarker and the treatment response aspects. Finally, we covered ten additional lncRNAs that were described only in lung cancers under their exosomal form.

Based on the literature covered here, it is evident that the interaction networks are far more complex than those presented here. Indeed, these networks are an extension of the following signaling pathways found in common for different diseases or lncRNAs: • The WNT/$\beta$-catenin signaling pathway, has been associated with H19, MALAT1, and HOTAIR in NSCLC \[[@B74-ijms-21-03580],[@B75-ijms-21-03580],[@B76-ijms-21-03580],[@B80-ijms-21-03580]\] • FENDRR and H19 are upstream regulators of the fibrosis and associated with the TGFB/SMAD3 signaling pathway in IPF \[[@B64-ijms-21-03580],[@B65-ijms-21-03580]\] • MEG3 and HOTAIR target the apoptosis pathway in COPD and NSCLC, respectively \[[@B70-ijms-21-03580],[@B81-ijms-21-03580]\]. • GAS5, TUG1, H19, and MALAT1 are upstream regulators of the PTEN/PI3K/AKT signaling pathway in NSCLC \[[@B77-ijms-21-03580],[@B78-ijms-21-03580],[@B82-ijms-21-03580],[@B83-ijms-21-03580],[@B111-ijms-21-03580],[@B135-ijms-21-03580],[@B235-ijms-21-03580]\] • ANRIL (CDKN2B-AS1) is an upstream regulator of the P53 signaling pathway in both IPF and NSCLC \[[@B63-ijms-21-03580]\]. Hence, all these studies on lncRNAs increased the list of upstream regulators of crucial cancer signaling pathways.

These lncRNAs have, therefore, the potential to sustain the tumor state of a cell. They were otherwise previously described as oncogenes and tumor-suppressors in lung cancers. In this context, H19, HOTAIR, MALAT1, and CDKN2B-AS1 are oncogenic lncRNAs \[[@B87-ijms-21-03580],[@B176-ijms-21-03580],[@B249-ijms-21-03580],[@B250-ijms-21-03580],[@B251-ijms-21-03580]\], while MEG3, FENDRR, and GAS5 are tumor suppressor lncRNAs \[[@B116-ijms-21-03580],[@B154-ijms-21-03580],[@B252-ijms-21-03580],[@B253-ijms-21-03580],[@B254-ijms-21-03580],[@B255-ijms-21-03580]\]. Intriguingly, TUG1 can be one or the other regarding lung cancer subtype. TUG1 would, therefore, act as an oncogene in SCLCs and many human cancers, but would act as a tumor-suppressor in NSCLCs \[[@B256-ijms-21-03580]\]. Therefore, such versatile behavior suggests either a tumor-specific mechanism of action or the presence of an upstream regulator with a tumor-dependent expression.

Moreover, we can link these interaction networks to the hallmarks of cancer. Due to their implication in multiple steps of the cancer progression, we can group the eight lncRNAs according to Hanahan and Weinberg's classification \[[@B257-ijms-21-03580]\] under the following hallmarks: ⋄*Genome instability and mutation:* MALAT1 and CDKN2B-AS1 may be key players of the "Genome instability and mutation" hallmark since they can decrease the expression levels of PARP1 \[[@B87-ijms-21-03580],[@B121-ijms-21-03580],[@B171-ijms-21-03580]\]. H19 may also contribute to the "Genome instability and mutation" as well as the "Evading growth suppressors" hallmarks. CSC exposure induces an overall increase of H3K27me3 levels, which would repress many genes \[[@B74-ijms-21-03580]\]. However, RIOX2 may demethylate H19 before the DNA-repair gene MGMT and the cyclin-dependent kinase inhibitor p16-CDKN2A are methylated \[[@B74-ijms-21-03580],[@B139-ijms-21-03580]\]. Subsequently, a decreased level of MGMT would lead to chromosomal alterations, while a decrease in p16-CDKN2A would lead to inhibit the cell cycle arrest in G1 and G2 phases.⋄*Activating invasion and metastasis:* FENDRR may be a key player of the "Activating invasion and metastasis" hallmark. The low FENDRR expression observed in NSCLC tumor tissues allows the ECM degradation by the metalloproteinases and thus facilitates the metastasis. Indeed, under normal conditions, FENDRR is supposed to sequester hsa-miR-761, which will permit the increase of the metalloproteinase inhibitor TIMP2, leading to the degradation of the extracellular matrix \[[@B196-ijms-21-03580]\].⋄*Resisting cell death:* MALAT1, MEG3, and CDKN2B-AS1 may be key actors of the "Resisting cell death" hallmark. CDKN2B-AS1 decreases cleaved-CASP3 while increasing BCL2 and CASP3 expression \[[@B87-ijms-21-03580],[@B121-ijms-21-03580]\]. High levels of MEG3 reduces CASP3 through hsa-miR-205-5 sequestration \[[@B154-ijms-21-03580],[@B157-ijms-21-03580],[@B160-ijms-21-03580]\]. These high levels can also decrease the expression of BIRC5 \[[@B118-ijms-21-03580]\]. MALAT1 can also decrease cleaved-CASP3 levels \[[@B171-ijms-21-03580]\]. Subsequently, in NSCLCs, cleaved-CASP3 is decreased, while BCL2, BIRC5, and CASP3 is increased, which leads to escape apoptosis.⋄*Sustaining and proliferative signaling:* GAS5, TUG1, MALAT1, H19, and HOTAIR may be key actors of the "Sustaining and proliferative signaling" hallmark in NSCLCs. High GAS5 and low HOTAIR levels combined with EGFR inhibitors, increase the sensitivity to treatment \[[@B110-ijms-21-03580],[@B114-ijms-21-03580]\]. GAS5, TUG1, H19, and MALAT1 are upstream regulators of the PTEN/PI3K/AKT signaling pathway. H19 recruits EZH2 to repress PTEN expression \[[@B135-ijms-21-03580]\]. MALAT1 is involved in the upregulation of PIK3CA \[[@B77-ijms-21-03580]\] and phospho-STAT3 \[[@B171-ijms-21-03580]\], and in the phosphorylation of AKT1 and MTOR \[[@B79-ijms-21-03580],[@B102-ijms-21-03580]\]. Finally, TUG1 and GAS5 can release PTEN expression, respectively, through hsa-miR-221 and hsa-miR-21-5p, hsa-miR-205-5p sequestration \[[@B82-ijms-21-03580],[@B83-ijms-21-03580],[@B111-ijms-21-03580],[@B235-ijms-21-03580]\]. Subsequently, in NSCLCs, PTEN is downregulated, while PIK3CA, phospho-STAT3, phospho-AKT1, and phospho-MTOR are increased, thus enhancing the cellular proliferation.

The eight lncRNAs may provide an interesting angle to circumvent the treatment resistances observed in lung cancers. Throughout the review, we listed treatment resistance to Cisplatin, Vincristine, Paclitaxel, Erlotinib, Atractylenolide 1, Adriamycin, Etoposide, Crizotinib, Gefitinib, and ionizing radiations. Surprisingly, HOTAIR alone was involved in the resistance to Crizotinib, Cisplatin, Erlotinib, and Atractylenolide 1 in NSCLC cells \[[@B81-ijms-21-03580],[@B112-ijms-21-03580],[@B113-ijms-21-03580],[@B114-ijms-21-03580]\], and to Cisplatin, Adriamycin, and Etoposide in SCLC cells \[[@B115-ijms-21-03580]\]. Although these results require confirmation, HOTAIR could be a promising target for future treatments. These results also underline the importance of studying lncRNAs in lung cancer.

The lncRNAs described here may be promising non-invasive biomarkers for the diagnosis or prognosis of asthma, COPD, and lung cancers. Indeed, GAS5, MEG3, MALAT1, or CDKN2B-AS1 may be used to diagnose asthma \[[@B58-ijms-21-03580],[@B59-ijms-21-03580],[@B61-ijms-21-03580]\]. TUG1 could be used to diagnose the COPD, and in association with CDKN2B-AS1, it could also help predict acute exacerbations in COPD patients \[[@B67-ijms-21-03580],[@B71-ijms-21-03580]\]. In IPF patients, CDKN2B-AS1 is again a new biomarker that could predict the occurrence of lung cancers \[[@B63-ijms-21-03580]\]. In lung cancers, MALAT1 and H19 are interesting for the diagnosis of NSCLCs \[[@B89-ijms-21-03580],[@B90-ijms-21-03580],[@B91-ijms-21-03580],[@B92-ijms-21-03580],[@B93-ijms-21-03580]\]. TUG1 is also a promising biomarker for diagnosis of LUAD \[[@B86-ijms-21-03580]\], whereas H19 or HOTAIR can help discriminate SCC from LUAD \[[@B109-ijms-21-03580]\]. Nevertheless, while being very encouraging results, most of these studies lack some confirmation from additional studies in large independent cohorts. Furthermore, the majority of these lncRNAs studied as individual biomarkers may help define better the classification of lung diseases. For example, using machine learning algorithms on previously established biomarkers combined with these lncRNAs, new disease subtypes may be revealed.

Accumulative pieces of evidence display lncRNAs as communication entities to regulate their micro-environment, thus being potentially involved in a local disease spread. While non-cancerous diseases have received some attention, such as osteoarthritis or chronic inflammatory diseases including rheumatoid arthritis, systemic lupus erythematosus, and psoriasis \[[@B258-ijms-21-03580]\], we mentioned the lack of studies covering exosomal-lncRNAs in asthma, COPD, and IPF. Hence, further efforts are needed to identify exosomal-lncRNAs in these three lung diseases. Conversely, the studies on exosomal-lncRNAs in lung focused on cancers. Although we did not find any shreds of evidence that exosomes transport MEG3, FENDRR, TUG1, and CDKN2B-AS1 in lung cancers, the mechanisms of action of these lncRNAs strongly suggest their involvement in cancer invasion. First, these lncRNAs may trigger important hallmarks of cancers, such as "Genome instability and mutation" for CDKN2B-AS1 \[[@B87-ijms-21-03580],[@B121-ijms-21-03580]\], "Activating invasion and metastasis" for FENDRR \[[@B196-ijms-21-03580]\], "Resisting cell death" for MEG3 and CDKN2B-AS1 \[[@B118-ijms-21-03580],[@B154-ijms-21-03580],[@B157-ijms-21-03580],[@B160-ijms-21-03580],[@B207-ijms-21-03580]\], and "Sustaining and proliferative signaling" for TUG1 \[[@B83-ijms-21-03580]\]. Secondly, previous studies in other cancers found an exosomal expression of MEG3, TUG1, and CDKN2B-AS1 \[[@B163-ijms-21-03580],[@B164-ijms-21-03580],[@B165-ijms-21-03580],[@B201-ijms-21-03580],[@B202-ijms-21-03580],[@B215-ijms-21-03580]\]. These findings suggest that MEG3, TUG1, and CDKN2B-AS1 may also be involved in lung cancer intercellular communication. Surprisingly, FENDRR remains unassociated with exosomes in any diseases. Nevertheless, its implication in invasion and metastasis \[[@B196-ijms-21-03580]\] suggests a late expression during the tumor progression, which could explain the lack of literature.

Altogether, throughout these numerous studies, we first underlined the importance of describing the lncRNAs mechanisms of action. By continuously seeking their putative regulators and downstream targets, new diagnostic tools and further treatments may arise. This review also compiled knowledge on exosomal-lncRNAs in lung diseases, and emphasize the essential position of some lncRNAs in the transcription regulation. Hence, we would be thrilled to read more investigations, in lung cancer, on exosomal MEG3, FENDRR, TUG1, and CDKN2B-AS1 or treatment resistance involving HOTAIR. We would be even more thrilled to read investigations on exosomal-lncRNAs in asthma, COPD, and IPF. Here, we highlighted eight well-described members of the lncRNAs' ocean. While these lncRNAs may trigger new research interests, it is of prime importance to identify all of them and to describe their mechanisms of action to better understand lung diseases.
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The following abbreviations are used in this manuscript:

**General**

Abbreviation

Full name

AECOPD

acute exacerbations of COPD

ANCT

Adjacent Non-Cancerous Tissue

ASM

Airway Smooth Muscle

BA-E

Bronchial asthma at exacerbation

BA-R

Bronchial asthma at remission

BEAS-2B

Bronchial epithelial cells

ceRNA

competing endogenous RNA

CDK

Cyclin Dependent Kinase

COPD

Chronic Obstructive Pulmonary Disease

CS

Cigarette Smoke

CSC

Cancer Stem Cell

CSE

Cigarette Smoke Extract

DDP

Cisplatine

EMT

Epithelial Mesenchymal Transition

FEV_1

Forced expiratory volume in 1 second

FFMI

Fat-free mass index

FVC

Forced vital capacity

GINA

Global Initiative for Asthma

H3K9me3

H3 lysine 9 tri-methylation

H3K27me3

H3 lysine 27 tri-methylation

HBE

Human Bronchial Epithelial cells

HRE

Hypoxia-Responsive Element

HNSCC

head-and-neck squamous cell carcinoma

IPF

Idiopathic Pulmonary Fibrosis

LD

linear dichroism

LDL

low-density lipoprotein

LSCC

Lung Squamous Cell Carcinoma

lncRNA

long non-coding RNA

LTB4

Leukotriene B4

LUAD

Lung Adenocarcinoma

MET

Mesenchymal Epithelial Transition

NAT

Natural Antisense transcripts

NSCLC

Non Small Cell Lung Cancer

OS

Overall Survival

OSCC

Oral Squamous Cell Carcinoma

PRC

Polycomb Repressive Complex

PTX

Paclitaxel

SCC

Squamous Cell Carcinoma

SCLC

Small Cell Lung Cancer

SNP

Single Nucleotide polymorphism

TCGA

The Cancer Genome Atlas

TNM

Tumor-Node--Metastasis:

TNM

T: Extent of the primary tumor,

TNM

N: lymph node involvement,

TNM

M: metastatic disease

WHO

World Health Organization

**Signaling Pathway**

Signaling Pathway

KEGG ID

AKT/MTOR signaling pathway

hsa04150

Apoptosis signaling pathway

hsa04210

EGFR pathway

hsa01521

NF-

κ

B signaling pathway

hsa04064

PTEN/PI3K/AKT signaling pathway

hsa04151

TGFB/SMAD3 signaling pathway

hsa04350

T-cell receptor signaling pathway

hsa04660

Th17 cell differentiation

hsa04659

P53 signaling pathway

hsa04115

WNT/

β

-catenin signaling pathway

hsa04310

**miRNAs**

Mirbase ID

HGNC symbol

Mirbase accession

hsa-miR-101-3p

MIR101-1

MIMAT0000099

hsa-miR-106a

MIR106A

MI0000113

hsa-miR-106b

MIR106B

MI0000734

hsa-miR-107

MIR107

MI0000114

hsa-miR-124-1

MIR124-1

MI0000443

hsa-miR-125a

MIR125A

MI0000469

hsa-miR-135b-5p

MIR135B

MIMAT0000758

hsa-miR-140

MIR140

MI0000456

hsa-miR-142-3p

MIR142

MIMAT0000434

hsa-miR-145

MIR145

MI0000461

hsa-miR-145-5p

MIR145

MIMAT0000437

hsa-miR-148a

MIR148A

MI0000253

hsa-miR-15a

MIR15A

MI0000069

hsa-miR-195

MIR195

MI0000489

hsa-miR-196b

MIR196B

MI0001150

hsa-miR-197-3p

MIR197

MIMAT0000227

hsa-miR-17

MIR17

MI0000071

hsa-miR-196a-1

MIR196A1

MI0000238

hsa-miR-196a-2

MIR196A2

MI0000279

hsa-miR-200

MIR200 family

hsa-miR-200 family

hsa-miR-200a

MIR200A

MI0000737

hsa-miR-200a-3p

MIR200A

MIMAT0000682

hsa-miR-200b

MIR200B

MI0000342

hsa-miR-200c

MIR200C

MI0000650

hsa-miR-203a

MIR203A

MI0000283

hsa-miR-203b

MIR203B

MI0017343

hsa-miR-204

MIR204

MI0000284

hsa-miR-205-5p

MIR205

MIMAT0000266

hsa-miR-206

MIR206

MI0000490

hsa-miR-21

MIR21

MI0000077

hsa-miR-21-5p

MIR21

MIMAT0000076

hsa-miR-210

MIR210

MI0000286

hsa-miR-214

MIR214

MI0000290

hsa-miR-214-3p

MIR214

MIMAT0000271

hsa-miR-217

MIR217

MI0000293

hsa-miR-218-1

MIR218-1

MI0000294

hsa-miR-218-5p

MIR218-1

MIMAT0000275

hsa-miR-218-2

MIR218-2

MI0000295

hsa-miR-221

MIR221

MI0000298

hsa-miR-23a

MIR23A

MI0000079

hsa-miR-29b-3p

MIR29B1

MIMAT0000100

hsa-miR-301b

MIR301B

MI0005568

hsa-miR-3163

MIR3163

MI0014193

hsa-miR-326

MIR326

MI0000808

hsa-miR-33a-5p

MIR33A

MIMAT0000091

hsa-miR-409-3p

MIR409

MIMAT0001639

hsa-miR-429

MIR429

MI0001641

hsa-miR-484

MIR484

MI0002468

hsa-miR-519a-1

MIR519A1

MI0003178

hsa-miR-519a-2

MIR519A2

MI0003182

hsa-miR-590-5p

MIR590

MIMAT0003258

hsa-miR-613

MIR613

MI0003626

hsa-miR-650

MIR650

MI0003665

hsa-miR-675

MIR675

MI0005416

hsa-miR-675-5p

MIR675

MIMAT0004284

hsa-miR-6515-3p

MIR6515

MIMAT0025487

hsa-miR-7-5p

MIR7-1

MIMAT0000252

hsa-miR-761

MIR761

MI0003941

hsa-let-7

MIRLET7 family

hsa-let-7 family

hsa-let-7d-5p

MIRLET7D

MIMAT0000065

**lncRNAs**

HGNC symbol

Alias

Full name

Type

Accession ID

AGAP2-AS1

AGAP2 Antisense RNA 1

NAT

ENSG00000255737

CCDC18-AS1

CCDC18 Antisense RNA 1

NAT

ENSG00000223745

CDKN2B-AS1

ANRIL

CDKN2B Antisense RNA 1

NAT

ENSG00000240498

FAS-AS1

FAS Antisense RNA 1

NAT

HGNC:37128

FENDRR

FOXF1 adjacent non-coding

developmental regulatory RNA

NAT

ENSG00000268388

GAPLINC

RP11-838N2.4

Gastric adenocarcinoma associated,

positive CD44 regulator, lincRNA

lincRNA

ENSG00000266835

GAS5

Growth Arrest Specific 5

NAT

ENSG00000234741

H19

H19 Imprinted Maternally Expressed Transcript

NAT,

ENSG00000130600

lincRNA

HAGLR

HOXD Antisense Growth-Associated lncRNA

NAT

ENSG00000224189

HOTAIR

HOX Transcript Antisense RNA

NAT

ENSG00000228630

HOTAIRM1

HOXA Transcript Antisense RNA,

Myeloid-Specific 1

NAT

ENSG00000233429

HOTTIP

HOXA Distal Transcript Antisense RNA

NAT

ENSG00000243766

HOXA-AS3

HOXA Cluster Antisense RNA 3

NAT

ENSG00000254369

HOXA10-AS

HOXA10 Antisense RNA

NAT

ENSG00000253187

HOXA11-AS

HOXA11 Antisense RNA

NAT

ENSG00000240990

LINC00312

Long Intergenic Non-Protein Coding RNA 312

lincRNA

HGNC:6662

LINC00861

Long Intergenic Non-Protein Coding RNA 861

lincRNA

ENSG00000245164

\-

lnc-MMP2-2

lnc-MMP2-2-1_dup1

lincRNA

NONHSAT142627

MEG3

Maternally Expressed 3

NAT

ENSG00000214548

MALAT1

Metastasis Associated LUAD Transcript 1

NAT

ENSG00000251562

NEAT1

Nuclear Paraspeckle Assembly Transcript 1

lincRNA

ENSG00000245532

PVT1

Pvt1 Oncogene

NAT

ENSG00000249859

THRIL

TNF And HNRNPL Related

Immunoregulatory lncRNA

lincRNA

ENSG00000280634

TUG1

Taurine Up-Regulated 1

lincRNA

ENSG00000253352

TBILA

TGF-Beta Induced LncRNA

lincRNA

ENSG00000261488

SOX2-OT

SOX2 Overlapping Transcript

NAT

ENSG00000242808

UCA1

Urothelial Cancer Associated 1

lincRNA

ENSG00000214049

ZEB1-AS1

ZEB1 Antisense RNA 1

NAT

ENSG00000237036

**Genes**

HGNC symbol

Alias

Full name

Accession ID

ABCB1

MDR1

ATP Binding Cassette Subfamily B Member 1

ENSG00000085563

ABCC1

MRP1

ATP Binding Cassette Subfamily C Member 1

ENSG00000103222

ABCC10

ATP binding cassette subfamily C member 10

ENSG00000124574

ACO1

IRP1

aconitase 1

ENSG00000122729

ACTA2

α

SMA

Actin

α

2, Smooth Muscle

ENSG00000107796

AGO1

Argonaute RISC Catalytic Components 1

ENSG00000092847

AGO2

Argonaute RISC Catalytic Components 2

ENSG00000123908

AGO3

Argonaute RISC Catalytic Components 3

ENSG00000126070

AGO4

Argonaute RISC Catalytic Components 4

ENSG00000134698

AKT1

Akt

AKT Serine/Threonine Kinase 1

ENSG00000142208

APC

APC Regulator Of WNT Signaling Pathway

ENSG00000134982

BAX

BCL2 associated X, apoptosis regulator

ENSG00000087088

BCL2

Bcl-2

BCL2 apoptosis regulator

ENSG00000171791

BCL2L1

Bcl-xl

BCL2 Like 1

ENSG00000171552

BECN1

Beclin1

ENSG00000126581

BIRC5

survivin

Baculoviral IAP Repeat Containing 5

ENSG00000089685

BRCA1

BRCA1 DNA Repair Associated

ENSG00000012048

CASC9

Cancer Susceptibility 9

ENSG00000249395

CASP3

caspase-3

Caspase 3

ENSG00000164305

CAV1

CAV-1

Caveolin 1

ENSG00000105974

CCND1

Cyclin D1

ENSG00000110092

CELF1

CUGBP Elav-Like Family Member 1

ENSG00000149187

CD274

PD-L1

CD274 Molecule

ENSG00000120217

CDH1

E-cadherin

Cadherin 1

ENSG00000039068

CDH13

Cadherin 13

ENSG00000140945

CDH2

N-cadherin

Cadherin 2

ENSG00000170558

CDKN1A

p21

CDK Inhibitor 1A

ENSG00000124762

CDKN1B

p27

CDK Inhibitor 1B

ENSG00000111276

CDKN2A

p14, p16, p19

CDK Inhibitor 2A

ENSG00000147889

CDKN2B

p15

CDK Inhibitor 2B

ENSG00000147883

COL1A1

Collagen type I

α

1 chain

ENSG00000108821

CBX7

Chromobox 7

ENSG00000100307

CTNNB1

β

-catenin

Catenin

β

1

ENSG00000168036

CTNND1

Catenin

δ

1

ENSG00000198561

CXCL5

C-X-C Motif Chemokine Ligand 5

ENSG00000163735

CXCL8

IL8

C-X-C Motif Chemokine Ligand 8

ENSG00000169429

DACH1

Dachshund Family Transcription Factor 1

ENSG00000276644

DAPK1

DAPK

Death Associated Protein Kinase 1

ENSG00000196730

DGCR8

DGCR8 Microprocessor Complex Subunit

ENSG00000128191

DLK1

δ

Like Non-Canonical Notch Ligand 1

ENSG00000185559

DIO3

Iodothyronine Deiodinase 3

ENSG00000197406

DNMT1

DNA Methyltransferase 1

ENSG00000130816

DNMT3B

DNMT3b

DNA Methyltransferase 3

β

ENSG00000088305

DUSP6

Dual Specificity Phosphatase 6

ENSG00000139318

E2F1

E2F Transcription Factor 1

ENSG00000101412

E2F3

E2F Transcription Factor 1

ENSG00000112242

EDNRB

Endothelin Receptor Type B

ENSG00000136160

EED

Embryonic Ectoderm Development

ENSG00000074266

EGFR

Epidermal Growth Factor Receptor

ENSG00000146648

EIF4A3

eIF4AIII

Eukaryotic Translation Initiation Factor 4A3

ENSG00000141543

ELAVL1

HuR

ELAV Like RNA Binding Protein 1

ENSG00000066044

EPAS1

Endothelial PAS Domain Protein 1

ENSG00000116016

ESR2

ER

β

Estrogen Receptor 2

ENSG00000140009

EWSR1

EWS RNA Binding Protein 1

ENSG00000182944

EZH1

Enhancer Of Zeste 1 PRC2 Subunit

ENSG00000108799

EZH2

Enhancer Of Zeste 2 PRC2 Subunit

ENSG00000106462

FAS

Fas Cell Surface Death Receptor

ENSG00000026103

Fgf1

Fibroblast growth factor 1

ENSRNOG00000013867

FMR1

FMRP

FMRP Translational Regulator 1

ENSG00000102081

FXR1

FMR1 Autosomal Homolog 1

ENSG00000114416

FN1

Fibronectin 1

ENSG00000115414

FOXA1

FoxA1

Forkhead Box A1

ENSG00000129514

FOXA2

FoxA2

Forkhead Box A2

ENSG00000125798

FOXF1

Forkhead Box F1

ENSG00000103241

FOXF2

Forkhead Box F2

ENSG00000137273

FOXN1

Forkhead Box N1

ENSG00000109101

FOXP3

Forkhead Box P3

ENSG00000049768

FUS

FUS RNA Binding Protein

ENSG00000089280

HELLS

LSH

Helicase, Lymphoid Specific

ENSG00000119969

HES1

hes family bHLH transcription factor 1

ENSG00000114315

HEY1

hes related family bHLH transcription factor

with YRPW motif 1

ENSG00000164683

HIF1A

HIF-1

α

Hypoxia Inducible Factor 1 Subunit

α

ENSG00000100644

HOXA1

Homeobox A1

ENSG00000105991

HOXA10

Homeobox A10

ENSG00000253293

HOXA11

Homeobox A11

ENSG00000005073

HOXB7

Homeobox B7

ENSG00000260027

HNRNPA2B1

hnRNPA2B1

Heterogeneous Nuclear Ribonucleoprotein A2/B1

ENSG00000122566

HNRNPC

Heterogeneous Nuclear Ribonucleoprotein C

ENSG00000092199

HNRNPL

Heterogeneous Nuclear Ribonucleoprotein L

ENSG00000104824

IGF1R

IGF-IR

Insulin Like Growth Factor 1 Receptor

ENSG00000140443

IGF2

Insulin Like Growth Factor 2

ENSG00000167244

IGF2BP1

IGF2 MRNA Binding Protein 1

ENSG00000159217

IGF2BP2

IGF2 MRNA Binding Protein 2

ENSG00000073792

IGF2BP3

IGF2 MRNA Binding Protein 3

ENSG00000136231

IL1A

IL1

α

Interleukin 1

α

ENSG00000115008

IL1B

IL1

β

inflammatory cytokines Interleukin 1

β

ENSG00000125538

IL6

Interleukin 6

ENSG00000136244

IL17A

IL17

Interleukin 17A

ENSG00000112115

IL22

Interleukin 22

ENSG00000127318

JARID2

Jumonji And AT-Rich Interaction Domain Containing 2

ENSG00000008083

JUN

c-Jun

Jun Proto-Oncogene, AP-1 Transcription Factor Subunit

ENSG00000177606

KDM1A

LSD1

Lysine Demethylase 1A

ENSG00000004487

KLF2

Kruppel Like Factor 2

ENSG00000127528

KLF4

Kruppel Like Factor 4

ENSG00000136826

KRT14

Keratin 14

ENSG00000186847

KRT19

Cyfra21-1

Keratin 19

ENSG00000171345

LIMK2

LIMK2b

LIM Domain Kinase 2

ENSG00000182541

LIN28B

Lin-28 Homolog B

ENSG00000187772

LRP1

LDL receptor-related protein-1

ENSG00000123384

MACC1

MET Transcriptional Regulator MACC1

ENSG00000183742

MAP1LC3A

LC3I

Microtubule Associated Protein 1 Light Chain 3

α

ENSG00000101460

MAP1LC3B

LC3II

Microtubule Associated Protein 1 Light Chain 3

β

ENSG00000140941

MAPK1

ERK, ERK2, MAPK

Mitogen-Activated Protein Kinase 1

ENSG00000100030

MAPK3

ERK1

Mitogen-Activated Protein Kinase 3

ENSG00000102882

MAPK8

JNK

Mitogen-Activated Protein Kinase 8

ENSG00000107643

MAPK9

Mitogen-Activated Protein Kinase 9

ENSG00000050748

MAP2K1

MEK1

Mitogen-Activated Protein Kinase Kinase 1

ENSG00000169032

MAP2K2

MEK2

Mitogen-Activated Protein Kinase Kinase 2

ENSG00000126934

MCL1

MCL1 Apoptosis Regulator, BCL2 Family Member

ENSG00000143384

MDM2

MDM2 Proto-Oncogene

ENSG00000135679

MDK

MK

Midkine

ENSG00000110492

MIAT

Myocardial Infarction Associated Transcript

ENSG00000225783

MGMT

O-6-Methylguanine-DNA Methyltransferase

MGMT

MMP2

MMP-2

Matrix Metallopeptidase 2

ENSG00000087245

MMP9

MMP-9

Matrix Metallopeptidase 9

ENSG00000100985

MOV10

Mov10 RISC Complex RNA Helicase

ENSG00000155363

MTOR

mTOR

Mechanistic Target Of Rapamycin Kinase

ENSG00000198793

MYC

c-myc

MYC Proto-Oncogene, BHLH Transcription Factor

ENSG00000136997

MYOD1

MYOD

Myogenic differentiation 1

ENSG00000129152

NANOG

Nanog

Nanog Homeobox

ENSG00000111704

NEDD9

Neural Precursor Cell Expressed,

Developmentally Down-Regulated 9

ENSG00000111859

NF1

Neurofibromin 1

ENSG00000196712

NFKB1

NF-

κ

B

Nuclear Factor Kappa B Subunit 1

ENSG00000109320

PARP1

PARP

Poly(ADP-Ribose) Polymerase 1

ENSG00000143799

PCNA

Proliferating Cell Nuclear Antigen

ENSG00000132646

PDK1

Pyruvate Dehydrogenase Kinase 1

ENSG00000152256

PDPK1

3-Phosphoinositide Dependent Protein Kinase 1

ENSG00000140992

PHOX2A

Phox2a

Paired Like Homeobox 2A

ENSG00000165462

PIK3CA

PI3K

Phosphatidylinositol-4,5-Bisphosphate

3-Kinase Catalytic Subunit

α

ENSG00000121879

POU5F1

Oct3, Oct4

POU Class 5 Homeobox 1

ENSG00000204531

PRC1

Polycomb Repressive Complex 1

PRC2

Polycomb Repressive Complex 2

PTBP1

PTB

Polypyrimidine Tract Binding Protein 1

ENSG00000011304

PTEN

Phosphatase And Tensin Homolog

ENSG00000171862

PUM2

Pumilio RNA Binding Family Member 2

ENSG00000055917

RB1

Rb

RB Transcriptional Corepressor 1

ENSG00000139687

RELA

p65

RELA Proto-Oncogene, NF-KB Subunit

ENSG00000173039

REST

RE1 Silencing Transcription Factor

ENSG00000084093

RCOR1

CoREST

REST Corepressor 1

ENSG00000089902

RIOX2

mdig

Ribosomal Oxygenase 2

ENSG00000170854

RORA

RAR Related Orphan Receptor A

ENSG00000069667

ROCK2

Rho Associated Coiled-Coil

Containing Protein Kinase 2

ENSG00000134318

RORC

ROR

γ

t

RAR related orphan receptor C

ENSG00000143365

RPS6KB1

S6K1

Ribosomal Protein S6 Kinase B1

ENSG00000108443

RTL1

Retrotransposon Gag Like 1

ENSG00000254656

SFN

14-3-3

σ

Stratifin

ENSG00000175793

SKP2

S-Phase Kinase Associated Protein 2

ENSG00000145604

SLC34A2

Solute Carrier Family 34 Member 2

ENSG00000157765

SMAD3

SMAD family member 3

ENSG00000166949

SNAI1

Snail Family Transcriptional Repressor 1

ENSG00000124216

SNAI2

SLUG

Snail Family Transcriptional Repressor 2

ENSG00000019549

SOX2

SRY-box transcription factor 2

ENSG00000181449

SOX7

SRY-Box Transcription Factor 7

ENSG00000012048

SOX9

SRY-Box Transcription Factor 9

ENSG00000125398

SP1

Sp1 Transcription Factor

ENSG00000185591

SRSF1

SFRS1

Serine And Arginine Rich Splicing Factor 1

ENSG00000136450

STAT3

Signal transducer and activator of transcription 3

ENSG00000168610

SUZ12

SUZ12 Polycomb Repressive Complex 2 Subunit

ENSG00000178691

TARDBP

TDP43

TAR DNA Binding Protein

ENSG00000120948

TBILA

TGF-Beta Induced LncRNA

ENSG00000261488

TCF7

Transcription Factor 7

ENSG00000081059

TFAP2C

Transcription Factor AP-2

γ

ENSG00000087510

TGFB1

TGF

β

1

transforming growth factor

β

1

ENSG00000105329

TIA1

TIA1 Cytotoxic Granule Associated RNA Binding Protein

ENSG00000116001

TIAL1

TIA1 Cytotoxic Granule Associated RNA Binding Protein Like 1

ENSG00000151923

TIMP2

TIMP Metallopeptidase Inhibitor 2

ENSG00000035862

TNF

TNF

α

Tumor Necrosis Factor

ENSG00000232810

TNRC6A

TNRC6

Trinucleotide Repeat Containing Adaptor 6A

ENSG00000090905

TP53

tumor protein p53

ENSG00000141510

TP63

tumor protein p63

ENSG00000073282

TP73

tumor protein p73

ENSG00000078900

U2AF2

U2AF65

U2 Small Nuclear RNA Auxiliary Factor 2

ENSG00000063244

ULK1

Unc-51 Like Autophagy Activating Kinase 1

ENSG00000177169

UPF1

UPF1 RNA Helicase And ATPase

ENSG00000005007

VIM

vimentin

ENSG00000026025

WNT10A

Wnt 10a

Wnt Family Member 10A

ENSG00000135925

WNT2

Wnt 2

Wnt Family Member 2

ENSG00000105989

WNT3A

Wnt Family Member 3A

ENSG00000154342

WNT5A

Wnt 5a

Wnt Family Member 5A

ENSG00000114251

WNT6

Wnt 6

Wnt Family Member 6

ENSG00000115596

YAP1

Yes associated protein 1

ENSG00000137693

ZC3H7B

Zinc Finger CCCH-Type Containing 7B

ENSG00000100403

ZEB1

Zinc Finger E-Box Binding Homeobox 1

ENSG00000148516

ZEB2

Zinc Finger E-Box Binding Homeobox 2

ENSG00000169554

![Exosomes in intercellular communication. Exosomes are nanovesicles (30--150 nm), which originate from the endosomal pathway by the formation of the early endosomes, late endosomes, and, ultimately, multivesicular bodies (MVBs). These vesicles are released to the extracellular microenvironment through MVB fusion to the plasma membrane and exocytosis. Exosomes contain many components of donor cells, including cell-surface proteins, lipids, metabolites, and genetic material, which confer them functional properties. Exosomes can transfer information to the target cell by (1) interacting with the cell surface, via a receptor-mediated mechanism, or by delivering its content to the target cell through (2) endocytosis, macropinocytosis or (3) through a direct fusion of exosomal membrane with the plasma membrane.](ijms-21-03580-g001){#ijms-21-03580-f001}

![The selected eight lncRNAs in Idiopathic Pulmonary Fibrosis (IPF): A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Up or down-regulated molecules are in purple. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g002){#ijms-21-03580-f002}

![The selected eight lncRNAs in Asthma: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Up or down-regulated molecules are in purple. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g003){#ijms-21-03580-f003}

![The selected eight lncRNAs in Chronic Obstructive Pulmonary Disease (COPD): A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Up or down-regulated molecules are in purple. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g004){#ijms-21-03580-f004}

![H19 in lung cancers: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g005){#ijms-21-03580-f005}

![MEG3 in lung cancers: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g006){#ijms-21-03580-f006}

![MALAT1 in lung cancers: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g007){#ijms-21-03580-f007}

![FENDRR in lung cancers: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g008){#ijms-21-03580-f008}

![TUG1 in lung cancers: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g009){#ijms-21-03580-f009}

![CDKN2B-AS1 in lung cancers: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g010){#ijms-21-03580-f010}

![HOTAIR in lung cancers: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Up or down-regulated molecules are in purple. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g011){#ijms-21-03580-f011}

![GAS5 in lung cancers: A network of lncRNA - miRNA - Protein interactions. Upregulated molecules are in green. Downregulated molecules are in red. Shape definitions are in grey. Gray arrows target the activated molecules. T-ended lines target the inhibited molecules. Square-ended lines represent a binding between molecules. Dashed-dot lines represent an association with unknown interaction.](ijms-21-03580-g012){#ijms-21-03580-f012}
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###### 

Downstream targets of the 8 lncRNAs described in lung diseases.

  Disease                                              LncRNA                        Expression                                                                       Location                                                      Action                                                                                   Targeted Pathway                                                   Downstream Targets                              References
  ---------------------------------------------------- ----------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------- --------------------------
  Asthma                                               CDKN2B-AS1                    up                                                                               BA-E & BA-R                                                   Pro-inflammatory                                                                         \-                                                                 TNF, IL17A                                      \[[@B58-ijms-21-03580]\]
  GAS5                                                 up                            Severe asthma CD4${}^{+}$T-cells                                                 Treg/Th17 balance                                             \-                                                                                       FOXP3, RORC                                                        \[[@B59-ijms-21-03580]\]                        
  BEAS-2B and primary human ASM cell cultures          Glucocorticoid activity       \-                                                                               \-                                                            \[[@B60-ijms-21-03580]\]                                                                                                                                                                                    
  MALAT1                                               up                            blood of highly-expressed IgE eosinophilic asthma                                Inhibits pathway                                              [T-cell receptor](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04660)             \-                                                                 \[[@B61-ijms-21-03580]\]                        
  Severe asthma CD4${}^{+}$T-cells                     Treg/Th17 balance             \-                                                                               FOXP3, RORC                                                   \[[@B59-ijms-21-03580]\]                                                                                                                                                                                    
  MEG3                                                 up                            Severe asthma CD4${}^{+}$T-cells                                                 Pro-inflammatory                                              [Th17 cell differentiation](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04659)   IL17A, IL22, RORC                                                  \[[@B59-ijms-21-03580]\]                        
  TUG1                                                 up                            ASM of Sprague Dawley rats                                                       Promotes cell proliferation and migration                     \-                                                                                       Fgf1                                                               \[[@B62-ijms-21-03580]\]                        
  IPF                                                  CDKN2B-AS1                    down                                                                             peripheral blood                                              Activates cell cycle arrest                                                              [P53](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04115)   CDKN2A, TP53                                    \[[@B63-ijms-21-03580]\]
  FENDRR                                               down                          fibrotic human lung cells and mouse primary lung fibroblasts                     Inhibits fibroblast activation & reduces pulmonary fibrosis   [TGFB / SMAD3](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04350)                ACO1                                                               \[[@B64-ijms-21-03580]\]                        
  H19                                                  up                            human pulmonary fibrotic tissues                                                 Induces fibrosis                                              [TGFB / SMAD3](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04350)                TGB1, SMAD3                                                        \[[@B65-ijms-21-03580]\]                        
  MEG3                                                 up                            pulmonary epithelial cells from IPF lung tissue                                  Promotes cell migration                                       \-                                                                                       TP63, KRT14, STAT3, YAP1, TP73, SOX2, HES1, HEY1                   \[[@B66-ijms-21-03580]\]                        
  COPD                                                 CDKN2B-AS1                    down                                                                             plasma of AECOPD                                              Anti-inflammatory                                                                        \-                                                                 TNF, IL1B, IL17A, CXCL8                         \[[@B67-ijms-21-03580]\]
  H19                                                  up                            Quadriceps of FFMI patients with COPD                                            Susceptibility to low FFMI                                    \-                                                                                       MYOD1                                                              \[[@B68-ijms-21-03580]\]                        
  HOTAIR                                               up                            CS-exposed male BALB/c mice & HBE cells treated with CSE                         \-                                                            \-                                                                                       IL6, CXCL8, CDH2, VIM, ACTA2, CDH1                                 \[[@B69-ijms-21-03580]\]                        
  MEG3                                                 up                            lung from COPD & CSE-treated 16HBE cells                                         Induces apoptosis and inflammation                            [Apoptosis](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04210)                   IL1B, IL6, TNF                                                     \[[@B70-ijms-21-03580]\]                        
  TUG1                                                 up                            sputum and lung from COPD smokers & non-smokers                                  Inhibits inflammation and airway remodelling                  \-                                                                                       DUSP6                                                              \[[@B71-ijms-21-03580]\]                        
  TGFB1 treated BEAS-2B and HFL1 cells                 Inhibits cell proliferation   \-                                                                               ACTA2, FN1                                                    \[[@B72-ijms-21-03580]\]                                                                                                                                                                                    
  SCLC                                                 HOTAIR                        up                                                                               H69 and H446 cell lines                                       Activates the pathway                                                                    NF-κB                                                              HOXA1                                           \[[@B73-ijms-21-03580]\]
  NSCLC                                                H19                           up                                                                               CDK-4/hTERT-immortalized HBEC                                 Associated with pathway activation                                                       WNT/β-catenin                                                      WNT2, WNT5A, WNT6, WNT10A, FOXN1, TCF7          \[[@B74-ijms-21-03580]\]
  MALAT1                                               up                            Tumor tissues and H1299 cell line                                                Associated with pathway activation                            WNT/β-catenin                                                                            \-                                                                 \[[@B75-ijms-21-03580],[@B76-ijms-21-03580]\]   
  H1299 and H520 cell lines                            Activates the pathway         [PTEN / PI3K / AKT](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04151)   BCL2, MMP9, PIK3CA, STAT3                                     \[[@B77-ijms-21-03580],[@B78-ijms-21-03580]\]                                                                                                                                                               
  Tumor tissues & A549 and H1299 cell lines            Regulates the pathway         [AKT / MTOR](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04150)          \-                                                            \[[@B79-ijms-21-03580]\]                                                                                                                                                                                    
  CDKN2B-AS1                                           down                          Peripheral blood of IPF                                                          Regulates the pathway                                         [P53](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04115)                         \-                                                                 \[[@B63-ijms-21-03580]\]                        
  HOTAIR                                               up                            95C, 95D and YTMLC-90 cell lines                                                 Regulates the pathway                                         WNT/β-catenin                                                                            RB1, E2F1                                                          \[[@B80-ijms-21-03580]\]                        
  A549, H460, H1299, NCI-H460 and HCC-827 cell lines   Activates the pathway         [Apoptosis](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04210)           pULK1                                                         \[[@B81-ijms-21-03580]\]                                                                                                                                                                                    
  GAS5                                                 down                          Tumor tissues & A549, NCI-H1299, H460, SK-MES-1, H157, and H358 cell lines       Regulates the pathway                                         [PTEN / PI3K / AKT](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04151)           PTEN                                                               \[[@B82-ijms-21-03580]\]                        
  TUG1                                                 down                          Tumor tissues & SPC-A1, NCI-H520, NCI-H520 and NCI-H1299 cell lines              Regulates the pathway                                         [PTEN / PI3K / AKT](https://www.genome.jp/dbget-bin/www_bget?pathway:hsa04151)           PTEN                                                               \[[@B83-ijms-21-03580]\]                        
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###### 

Potential biomarkers from the eight lncRNAs observed in lung diseases.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease                  Location                 LncRNA            Type                                                                               Value                                                                                                                                                         Relevancy                                                                                 References
  ------------------------ ------------------------ ----------------- ---------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ---------------------------
  Asthma                   CD4${}^{+}$T-cells       GAS5 / MEG3       expression                                                                         upregulated                                                                                                                                                   Up in asthmatic patients vs. healthy patients                                             \[[@B59-ijms-21-03580]\]

  peripheral whole blood   MALAT1                   expression        upregulated                                                                        Up in highly-expressed IgE eosinophilic asthmatic (EA) patients vs. healthy patients                                                                          \[[@B61-ijms-21-03580]\]                                                                  

  plasma                   CDKN2B-AS1               expression        upregulated                                                                        Up in patients with bronchial asthma vs. healthy patients                                                                                                     \[[@B58-ijms-21-03580]\]                                                                  

  COPD                     plasma                   CDKN2B-AS1        expression                                                                         downregulated                                                                                                                                                 Down in patients with acute exacerbations of COPD vs. stable COPD or healthy patients     \[[@B67-ijms-21-03580]\]

  sputum & lung            TUG1                     expression        upregulated                                                                        Up in COPD patients with or without smoking history                                                                                                           \[[@B71-ijms-21-03580]\]                                                                  

  IPF                      peripheral whole blood   CDKN2B-AS1        expression                                                                         downregulated                                                                                                                                                 Down in IPF patients, vs. healthy controls\                                               \[[@B63-ijms-21-03580]\]
                                                                                                                                                                                                                                                                                                                       May promote the occurrence of lung cancers                                                

  Lung\                    constitutive DNA         H19               polymorphism                                                                       rs217727 C \>T                                                                                                                                                Associated with increased risk of lung cancer in meta-analysis                            \[[@B84-ijms-21-03580]\]
  cancers                                                                                                                                                                                                                                                                                                                                                                                                        

  MEG3                                              rs4081134 G \>A   Genotype \[AA\] associated with lung cancer risk in chinese northeast population   \[[@B85-ijms-21-03580]\]                                                                                                                                                                                                                                

  LUAD                     serum                    TUG1              expression                                                                         upregulated                                                                                                                                                   Up in LUAD patients vs. healthy patients                                                  \[[@B86-ijms-21-03580]\]

  tumor                    CDKN2B-AS1               expression        upregulated                                                                        Up in cell lines & positively correlated with the differentiation grade and the TNM stages                                                                    \[[@B87-ijms-21-03580]\]                                                                  

  tumor                    FENDRR                   expression        downregulated                                                                      Strongly associated with High TNM 1 stage in LUAD patients vs. healthy patients.\                                                                             \[[@B88-ijms-21-03580]\]                                                                  
                                                                                                                                                         Predicts LUAD cancer vs. healthy state when associated with LINC00312                                                                                                                                                                                   

  NSCLC                    plasma                   H19               expression                                                                         upregulated                                                                                                                                                   Up in NSCLC vs. begnin lung disease                                                       \[[@B89-ijms-21-03580]\]

  serum                    MALAT1                   expression        downregulated                                                                      Down in patients with NSCLC vs. healthy patients                                                                                                              \[[@B90-ijms-21-03580],[@B91-ijms-21-03580],[@B92-ijms-21-03580],[@B93-ijms-21-03580]\]   

  tumor                    CDKN2B-AS1               expression        upregulated                                                                        Correlated with poor patient OS                                                                                                                               \[[@B94-ijms-21-03580]\]                                                                  

  GAS5                     expression               downregulated     Down in male subjects vs. corresponding ANCTs.                                     \[[@B95-ijms-21-03580]\]                                                                                                                                                                                                                                

  H19                      expression               upregulated       Up in stage III and IV vs. stage I and II & negatively correlated with OS          \[[@B96-ijms-21-03580],[@B97-ijms-21-03580]\]                                                                                                                                                                                                           

  HOTAIR                   expression               upregulated       Up in patients with stage III and IV vs. stage I and II.\                          \[[@B98-ijms-21-03580],[@B99-ijms-21-03580],[@B100-ijms-21-03580]\]                                                                                                                                                                                     
                                                                      Positively correlated with greater tumor size,\                                                                                                                                                                                                                                                                                            
                                                                      lymph node metastasis or lymph-vascular invasion,\                                                                                                                                                                                                                                                                                         
                                                                      short disease free interval, and reduced OS.                                                                                                                                                                                                                                                                                               

  MALAT1                   expression               upregulated       Associated with a poor prognosis and short OS.\                                    \[[@B76-ijms-21-03580],[@B79-ijms-21-03580],[@B101-ijms-21-03580],[@B102-ijms-21-03580],[@B103-ijms-21-03580],[@B104-ijms-21-03580],[@B105-ijms-21-03580]\]                                                                                             
                                                                      Associated with age, tumour size & TNM stage,\                                                                                                                                                                                                                                                                                             
                                                                      when combined to SOX9                                                                                                                                                                                                                                                                                                                      

  MEG3                     expression               downregulated     Associated with short-term survival                                                \[[@B106-ijms-21-03580]\]                                                                                                                                                                                                                               

  TUG1                     expression               downregulated     Associated with a high TNM stage and a poor patient outcome                        \[[@B105-ijms-21-03580],[@B107-ijms-21-03580],[@B108-ijms-21-03580]\]                                                                                                                                                                                   

  SCC                      sputum                   H19/HOTAIR        expression                                                                         \-                                                                                                                                                            Diagnosis of SCC vs. LUAD                                                                 \[[@B109-ijms-21-03580]\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Lung cancer treatment resistances associated to the eight lncRNAs described in lung diseases.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease              Treatment                                            LncRNA                                                Expression                                                              Relevancy                                           References
  -------------------- ---------------------------------------------------- ----------------------------------------------------- ----------------------------------------------------------------------- --------------------------------------------------- ---------------------------
  LUAD                 Gefitinib                                            GAS5                                                  down                                                                    Overexpression increases sensitivity to treatment   \[[@B110-ijms-21-03580]\]

  Ionizing radiation   Overexpression increases radiosensitivity            \[[@B111-ijms-21-03580]\]                                                                                                                                                         

  Cisplatine           HOTAIR                                               up                                                    Repression increases sensitivity to treatment                           \[[@B112-ijms-21-03580],[@B113-ijms-21-03580]\]     

  Erlotinib            Repression of PDK1 and HOTAIR-mediated EZH2\         \[[@B114-ijms-21-03580]\]                                                                                                                                                         
                       gene expression increases sensitivity to treatment                                                                                                                                                                                     

  Atractylenolide 1                                                                                                                                                                                                                                           

  SCLC                 Cisplatine                                           HOTAIR                                                up                                                                      Repression increases sensitivity to treatment       \[[@B115-ijms-21-03580]\]

  Adriamycin                                                                                                                                                                                                                                                  

  Etoposide                                                                                                                                                                                                                                                   

  NSCLC                Cisplatine                                           FENDRR                                                down                                                                    Negatively correlated with treatment response       \[[@B116-ijms-21-03580]\]

  GAS5                 down                                                 Could regulate chemo-resistance to treatment          \[[@B82-ijms-21-03580]\]                                                                                                    

  H19                  up                                                   Negatively correlated with treatment response         \[[@B96-ijms-21-03580]\]                                                                                                    

  MALAT1               up                                                   Increases resistance to treatment through positive\   \[[@B76-ijms-21-03580]\]                                                                                                    
                                                                            feedback loop with SOX9                                                                                                                                                           

  MEG3                 down                                                 Overexpression increases sensitivity to treatment     \[[@B117-ijms-21-03580],[@B118-ijms-21-03580],[@B119-ijms-21-03580]\]                                                       

  TUG1                 down                                                 Overexpression increases sensitivity to treatment     \[[@B83-ijms-21-03580]\]                                                                                                    

  Crizotinib           HOTAIR                                               up                                                    Repression increases sensitivity to treatment                           \[[@B81-ijms-21-03580]\]                            

  Paclitaxel           CDKN2B-AS1                                           up                                                    Inhibits sensitivity to treatment                                       \[[@B87-ijms-21-03580]\]                            

  Vincristine          MEG3                                                 down                                                  Overexpression increases sensitivity to treatment                       \[[@B117-ijms-21-03580],[@B120-ijms-21-03580]\]     

  OSCC                 Cisplatine                                           CDKN2B-AS1                                            up                                                                      Associated with Midkine to treatment resistance     \[[@B121-ijms-21-03580]\]
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
